

AMERICAN UNIVERSITY OF BEIRUT

CYTOKINE PROFILING IN CHRONIC
NEUROTOXOPLASMOSIS CAUSED BY THE KNOCK-OUT
PARASITE FOR THE BRADYZOITE MARKER *P18* IN THE
C57BL/6J MOUSE MODEL

by
KATIA SAWAYA, MD

A thesis
submitted in partial fulfillment of the requirements
for the degree of Master of Science
to the Department of Experimental Pathology, Immunology and Microbiology of the
Faculty of Medicine at the American University of Beirut.


Beirut, Lebanon
April 2016

AMERICAN UNIVERSITY OF BEIRUT

CYTOKINE PROFILING IN CHRONIC
NEUROTOXOPLASMOSIS CAUSED BY THE KNOCK-
OUT PARASITE FOR THE BRADYZOITE MARKER *P18*
IN THE C57BL/6J MOUSE MODEL

by
KATIA SAWAYA

Approved by:



Dr. Hiba El Hajj, Assistant Professor
Department of Internal Medicine

Advisor



Dr. Alexander Abdelnoor, Acting Chairperson & Professor
Department of Experimental Pathology, Immunology & Microbiology

Member of Committee



Dr. Hassan Zaraket, Assistant Professor
Department of Experimental Pathology, Immunology & Microbiology

Member of Committee



Dr. Ghassan Awar, Assistant Professor of Clinical Specialty
Department of Internal Medicine

Member of Committee

Date of thesis defense: April 20 2016

AMERICAN UNIVERSITY OF BEIRUT

THESIS RELEASE FORM

Student Name: Sawaya Katia Khaled

Master's Thesis
Dissertation

Master's Project

Doctoral

I authorize the American University of Beirut to: (a) reproduce hard or electronic copies of my thesis, dissertation, or project; (b) include such copies in the archives and digital repositories of the University; and (c) make freely available such copies to third parties for research or educational purposes.

I authorize the American University of Beirut, **three years after the date of submitting my thesis, dissertation, or project**, to: (a) reproduce hard or electronic copies of it; (b) include such copies in the archives and digital repositories of the University; and (c) make freely available such copies to third parties for research or educational purposes.

ACKNOWLEDGMENTS

Special thanks are for Dr. Hiba ElHajj, for her dedicated guidance, Mr. Nadim Tawil, for his great help in the technical work and for Mrs. Rita Hleihel, Mr. Martin Karam and Miss Rana ElHajj for their generous assistance whenever it was needed.

My recognition and gratitude are addressed to the committee members; Dr. Alexander Abdelnoor, Acting Chairperson of the Department of Experimental Pathology, Immunology & Microbiology, Dr. Hassan Zaraket, and Dr. Ghassan Awar.

Many thanks to our french collaborators Drs Maryse Lebrun and Jean-Francois Dubremetz for providing us with the wild type PRU Δ KU80 strain and to AUBMC Medical Practice Plan, CNRS-L, AUBMC SEED Grant, Cedre, and L'Oreal-UNESCO for women in science Levant and Egypt Regional Fellowship Program for their financial support.

AN ABSTRACT OF THE THESIS OF

Katia Sawaya for Master of Science
Major: Microbiology and Immunology

Title: Cytokine Profiling in Chronic Neurotoxoplasmosis caused by the knock-Out Parasite for the Bradyzoite Marker P18 in the C57BL/6J Mouse Model

Descriptive Statement: *Toxoplasma gondii* is an obligate intracellular parasite that forms chronic life-long bradyzoite cysts in the brain of infected humans. Our lab generated the Pru Δ KU80 Δ P18 strain in which the bradyzoite marker P18 was deleted and found that this strain displays a higher capacity of cyst formation when compared to the wild type strain Pru Δ KU80. Since the host immune response is the key player of controlling the switch between acute and chronic toxoplasmosis, we have investigated this immune response, through cytokine profiling, against the P18 knock-out strain using the C57BL/6J susceptible mouse model.

Introduction: *T. gondii* is capable of establishing an acute and/or latent chronic infection in a wide variety of hosts. IFN- γ is key driver that tightly controls the chronic cerebral infection, and activates microglial cells as well as other brain reaching wandering cells such as macrophages to produce nitric oxide (NO). NO, along with pro- and anti-inflammatory cytokines, triggers the conversion to bradyzoite forms and is critically important to control infection in C57BL/6 mice. We investigated the cyst forming capacity and the immune response upon infection with Pru Δ KU80 Δ P18 and Pru Δ KU80 strains in the brains of the susceptible C57BL/6J mice by measuring transcription levels of BAG-1, a bradyzoite marker in the brains of mice infected with either strain and comparing these levels as well as the transcription levels of various cytokines involved in the immune response against *T. gondii*.

Methods: C57BL/6 mice were infected with Pru Δ KU80 Δ P18 and Pru Δ KU80 strains and were treated with sulfadiazine to overcome the acute phase of toxoplasmosis. Blood was collected on day 7 post infection to verify the acute infection by the western blotting. Mice were sacrificed on weekly basis from week 2 until week 5. Total mRNA was extracted from the brains, and different immunomodulatory cytokines and chemokines (MCP-1, IL-12, IFN- γ , TNF α , iNOS, IL-1 β , IL-6, and IL-10) were measured in addition to the bradyzoite marker BAG-1 using Syber Green Real Time PCR.

Results: We have seen a clear difference in the amount of encysted bradyzoites in the brains of mice infected with Pru Δ KU80 Δ P18 and Pru Δ KU80 as reflected by the transcription levels of BAG-1 on day 28 post-infection We also have shown that Pru Δ KU80 Δ P18 stimulates higher levels of IFN- γ reaching a maximum at week 2 presumably leading to the recruitment of more IL-12 producing macrophages. This was consistent with MCP-1 levels that were also higher and

reached a maximum on week 3 post-infection in the *P18* knock strain. Since Nitric Oxide (NO) plays a vital role in controlling toxoplasmosis progression, and since inducible NOS (iNOS) levels are upregulated in brains of infected mice with type II *T.gondii*, we have shown that *PruΔKU80ΔP18* leads to higher levels of iNOS at all time points reaching a maximum at day 35, eventually controlling the infection. We also have seen that IL-10 increases over weeks presumably as an anti-inflammatory cytokine alleviating the disease burden. Pro-inflammatory cytokine transcription levels of IL-1 β and IL-6 showed opposite results to those of IL-10 at days 28 and 35 post-infection being higher in the brains of mice infected with *PRUΔKU80*.

Conclusion: The current study highlights the role of the bradyzoite marker P18 in shaping the brain immune response, allowing the understanding of key molecular mechanisms related to the neurotoxoplasmosis.

CONTENTS

| | |
|------------------------|-----|
| ACKNOWLEDGEMENTS | v |
| ABSTRACT..... | vi |
| LIST OF FIGURES..... | xi |
| LIST OF TABLES..... | xii |

Chapter

| | |
|---|----------|
| I. INTRODUCTION..... | 1 |
| A. History | 1 |
| B. Taxonomy | 3 |
| C. Host-cell invasion | 3 |
| D. Stages | 4 |
| 1. The Tachyzoite..... | 4 |
| 2. The Bradyzoite..... | 5 |
| E. Life Cycle | 8 |
| F. Epidemiology and Transmission | 10 |
| G. <i>Toxoplasma gondii</i> Pathogenesis..... | 12 |
| 1. In the immunocompetent host..... | 12 |
| 2. In the immunocompromised host | 12 |
| 3. In primo-infected pregnant women..... | 14 |
| H. Significance of <i>T. gondii</i> as an Experimental Model..... | 14 |
| I. <i>Toxoplasma gondii</i> Surface Markers | 15 |
| 1. The Tachyzoite Surface Antigen-1 (SAG-1)..... | 15 |

| | |
|--|-----------|
| 2. The Bradyzoite Antigen-1(BAG-1) marker | 16 |
| 3. The Bradyzoite Markers: p36, p34, p21 and p18..... | 16 |
| 4. The Bradyzoite Marker SAG-4 or P18..... | 17 |
| J. <i>Toxoplasma gondii</i> strains..... | 18 |
| K. A New genetic model of type II strains: PRU Δ KU80..... | 19 |
| 1. PRU Δ KU80 Δ P18..... | 20 |
| L. Immunology of <i>Toxoplasma gondii</i> | 21 |
| 1. Introduction | 21 |
| 2. Host immune Response during acute toxoplasmosis in Type II <i>Toxoplasma gondii</i> infection..... | 24 |
| 3. Host brain immune Response during the chronic phase of toxoplasmosis..... | 27 |
| M. Cytokine Summary..... | 29 |
| 1. Nitric Oxide (NO)..... | 29 |
| 2. IL-12..... | 30 |
| 3. IFN- γ | 30 |
| 4. TNF- α | 30 |
| 5. IL-6 and IL-1 β | 31 |
| 6. IL-10..... | 31 |
| 7. MCP-1/CCL-2..... | 31 |
| II. Material and Methods..... | 33 |
| A. Experimental Design | 33 |
| B. Ethical Statement..... | 34 |
| C. Maintenance of Parasites in Human Foreskin Fibroblasts (HFF)..... | 34 |
| D. The C57BL/6 mouse model..... | 34 |
| E. Verification of Infection by Western Blotting..... | 35 |
| F. Brain Harvesting and RNA Extraction..... | 36 |
| G. cDNA Synthesis..... | 37 |

| | |
|---|-----------|
| H. Quantitative Real-Time Polymerase Chain Reaction (qRt-PCR)..... | 38 |
| III. Results..... | 40 |
| A. PRU Δ KU80 and PRU Δ KU80 Δ P18 parasites successfully establish acute toxoplasmosis in C57/Bl6 mice..... | 40 |
| B. C57/BL6 mice infected with PRU Δ KU80 Δ P18 harbor more cysts than those infected with PRU Δ KU80 parasites..... | 41 |
| C. PRU Δ KU80 Δ P18 recruits more macrophages and dendritic cells than PRU Δ KU80 to the brain of C57/Bl6..... | 43 |
| D. PRU Δ KU80 Δ P18 induce higher levels of transcription of IL-12 when compared to PRU Δ KU80..... | 44 |
| E. PRU Δ KU80 Δ P18 induce significantly higher levels of transcription of IFN- γ when compared to PRU Δ KU80..... | 46 |
| F. PRU Δ KU80 Δ P18 and PRU Δ KU80 display a gradual increase of TNF- α in the brain of C57/BL6 mice over weeks post-infection with significantly higher levels of transcription of TNF- α in case of the P18 depleted strain..... | 47 |
| G. PRU Δ KU80 Δ P18 and PRU Δ KU80 display a different pattern of IL-6 transcript stimulation in the brain of C57/BL6 mice over weeks post-infection with peaks of IL-6 reached at d21 post-infection with PRU Δ KU80 Δ P18..... | 48 |
| H. PRU Δ KU80 Δ P18 and PRU Δ KU80 display a different pattern of IL-1 β transcript levels regulation in the brain of C57/BL6 mice over weeks post-infection..... | 50 |
| I. PRU Δ KU80 Δ P18 induces consistently higher levels of iNOS than PRU Δ KU80 in the brain of C57/BL6 mice over weeks post-infection..... | 51 |
| J. PRU Δ KU80 Δ P18 induces higher levels of IL-10 than PRU Δ KU80 in the brain of C57/BL6 mice..... | 53 |
| CONCLUSION..... | 55 |
| REFERENCES..... | 59 |

LIST OF FIGURES

| | |
|---|----|
| FIGURE 1. TAXONOMY FROM THE NCBI TAXONOMY DATABASE | 2 |
| FIGURE 2. T. GONDII INVASION OF HOST CELLS | 4 |
| FIGURE 3. ULTRASTRUCTURE OF T. GONDII. | 5 |
| FIGURE 4. BRADYZOITE CYST IN THE BRAIN OF A MOUSE INFECTED WITH THE VEG STRAIN TYPE II STRAIN OF T. GODII..... | 5 |
| FIGURE 5. SECTION OF THE CEREBRUM OF A PATIENT WITH AIDS | 7 |
| FIGURE 6. TOXOPLASMA GONDII LIFE CYCLE | 9 |
| FIGURE 7. TRANSMISSION OF T. GONDII | 11 |
| FIGURE 8. HOST CELL RESPONSES THAT CAN BE MODULATED BY TOXOPLASMA GONDII . | 22 |
| FIGURE 9. EFFECTOR MECHANISMS IN TYPE II TOXOPLASMOSIS | 22 |
| FIGURE 10. EFFECTOR MECHANISMS OF IFN γ -MEDIATED PARASITE ELIMINATION IN INFECTED CELLS | 23 |
| FIGURE 11. INTERFERON- γ (IFN γ) IS CRUCIAL FOR SURVIVAL DURING TOXOPLASMA GONDII INFECTION. | 26 |
| FIGURE 12. IL-10, AN IMPORTANT IMMUNOSUPPRESSOR | 27 |
| FIGURE 13. IMMUNE RESPONSE TO T. GONDII IN THE INFECTED BRAIN BY RESIDENT AND RECRUITED IMMUNE CELLS | 29 |
| FIGURE 14. EXPERIMENT TIMELINE | 32 |
| FIGURE 15. VERIFICATION OF T. GONDII INFECTION BY WESTERN BLOT..... | 40 |
| FIGURE 16. BAG-1 | 41 |
| FIGURE 17. MCP-1 | 43 |
| FIGURE 18. IL-12 | 44 |
| FIGURE 19. IFN- γ | 46 |
| FIGURE 20. TNF-A..... | 47 |
| FIGURE 21. IL-6..... | 48 |
| FIGURE 22. IL-1B..... | 50 |
| FIGURE 23. iNOS | 51 |
| FIGURE 24. IL-10..... | 53 |

List of Tables

| | |
|--|----|
| TABLE 1. DIFFERENCES BETWEEN TACHYZOITE AND BRADYZOITE STAGES OF TOXOPLASMA GONDII | 7 |
| TABLE 2. SYMPTOMS ASSOCIATED WITH THE REACTIVATION OF TOXOPLASMOSIS IN IMMUNOCOMPROMISED PATIENTS | 13 |
| TABLE 3. COMMON BRADYZOITE MARKERS..... | 17 |
| TABLE 4. THE 3 COMMON LINEAGES OF T. GONDII..... | 18 |
| TABLE 5. SUMMARY OF IMPORTANT CYTOKINES INVOLVED IN TOXOPLASMOSIS IMMUNE RESPONSE | 29 |
| TABLE 6. cDNA COMPONENTS UTILIZED FOR SYNTHESIS AND RESPECTIVE VOLUMES..... | 36 |
| TABLE 7. PRIMERS USED IN RT-PCR..... | 38 |

CHAPTER I

INTRODUCTION

A. History

In 1908, Nicolle and Manceaux came across a parasite they mistook for *Leishmania*, while experimenting on a rodent, *Ctenodactylus gundi*, in the laboratory of Charles Nicolle in Tunis (Nicolle and Manceaux, 1908) (Kean, 1972) (Ferguson, 2009) (Dubey, 2009). Little after, they had stumbled upon a major new parasite vastly distributed in all kinds of animals including birds and humans. They realized their major discovery, and in 1909 they named it *Toxoplasma gondii*, after its morphology, “Toxo” from the latin meaning arc, and “plasma” from the latin meaning life. During the same year of 1908, another scientist, Splendore, found the same parasite in a rabbit in Brazil, also mistaking it at first for *Leishmania* (Splendore, 1908) (Cross, 1947) (Dubey, 2014).

Findings of *T. gondii* continued to appear for several years in different hosts, but the first isolation of viable *T. gondii* from an animal host was at the hands of Sabin and Olitsky in 1937. They also showed that this parasite was obligate intracellular and that transmission could happen through inoculation of brain homogenates of an infected animal into a healthy one; they further went on, to deduce through experiments carried out on mice that the parasite can be transmitted through ingestion of infected tissues (Dubey, 2009).

This work was later followed by an isolation of *T. gondii* from human beings by Wolf et al. in 1939. This isolation came following a post-mortem examination of the nervous system of a child who died from encephalomyelitis at day 31 postnatally.

Granulomatous lesions were detected in the brain that contained an organism resembling *T. gondii* (Wolf 1939).

In 1991, Frenkle et al. successfully presented a vaccine, designated T-263 that prevents shedding of oocysts (infective stages of *T. gondii* if ingested) from its primary host, the domesticated cat (Frenkel, 1991). Another important hallmark came to be in 2005 after sequencing the whole *T. gondii* genome by Khan et al. (Khan et al., 2005).

Since then, many studies continued to be carried out on *T. gondii* spanning across its various aspects like morphology, life cycle, transmission, diseases, immunity, diagnosis, treatment, and potential vaccination, highlighting a world of knowledge on the biology of this parasite and its caused-disease.




Figure 1. Taxonomy from the NCBI taxonomy database (http://eol.org/pages/34045746/hierarchy_entries/51390122/overview)

B. Taxonomy

Toxoplasma gondii is a single-celled obligate intracellular parasite. It belongs to the domain Eukaryota, kingdom Alveolata, phylum Apicomplexa (Levine, 1977) (Figure 1). Furthermore, *T. gondii* belongs to the class coccidia, the order Eucoccidiorida, and genus *Toxoplasma* which contains only one species “*gondii*”.

Along with *Plasmodium spp.* which claims over a million lives each year (Manguin et al. 2010), *Toxoplasma gondii* is one of the most important apicomplexan parasites, affecting around 30% of the world’s population (Dubey, 2009). There are common several physical features among the apicomplexan parasites, the most important being the apical complex structure formed of a conoid with polar rings (Lee et al., 2000). In addition, there are secretory organelles named rhoptries, micronemes, and dense granules, which are tightly involved in the host-cell invasion mechanism.

C. Host-Cell Invasion

Host cell invasion is a conserved mechanism among all apicomplexan parasites. In *Toxoplasma gondii*, it involves an initial step of attachment to the host cell, and involving mostly the parasite micronemal proteins (MICs) with the host cell plasma membrane (Figure 2). A second step is the formation of a moving junction from micronemal and rhoptry neck proteins (RONs), propelling the parasite inside a protective parasitophorous vacuole formed mostly by parasitic rhoptry proteins (ROPs) and where the parasite actively replicates, involving host and parasite proteins as well as scavenging nutrients from the host cell, until lysing the host cell (Figure 2) (Soldati, Dubremetz, and Lebrun, 2001; Hunter and Sibley, 2012).




Figure 2. *T. gondii* Invasion of host cells. Hunter, Christopher A., and L. David Sibley. "Nature Reviews Microbiology 10.11 (2012): 766-778.

D. Stages responsible for acute and chronic toxoplasmosis

1. The Tachyzoite:

Previously known as the trophozoite from “trophicos”, meaning feeding in greek, the tachyzoite named as such by Frankel in 1973 is the fast replicating stage of *T. gondii* where “Tachos” means fast and “zoite” means life. This form is responsible for the acute phase of the infection. This was the form of the parasite that Nicolle and Manceaux came across in 1908 and described as crescent shaped (Gustafson et al., 1954). The tachyzoite, lacking any specialized locomotive structures, presents the apical structure formed of the conoid, rhoptries, micronemes, and dense granules (Dubey and Lindsay, 1998), in addition to the normal organelles of a eukaryotic cell but also an inherited plant structure called apicoplast involved in fatty acid synthesis (Figure 3).




Figure 3. Ultrastructure of *T. gondii* Ajioka, *Expert Review in Molecular Medicine*. <http://www.ermm.cbcu.cam.ac.uk>. Department of Pathology. University of Cambridge. Tennis Court Road. Cambridge. UK(2001).

Once inside the host cells of an intermediate host, the tachyzoites divide asexually by repeated endodyogeny, a process first described by Goldman et al. in 1958, in which two daughter parasites form inside the mother parasite killing it.

2. The Bradyzoite:




Figure 4. Bradyzoite cyst in the brain of a mouse infected with the VEG strain type II strain of *T. gondii* (Dubey et al., *Clin Microbiol Rev* 1998)

The Bradyzoite is the slow multiplying form of the parasite. The term was also suggested by Frenkel in 1973 to describe the encysted stage in the intermediate host tissues. The cyst was first recognized by Levaditi, Schoen, and Sanchis Bayarri in 1928 and the first cytological description was by Frenkel and Friedlander in 1951. Later on, when Dubey et al. discovered the oocyst they suggested that the cysts be called tissue cysts to avoid confusion. These tissue cysts have been described to have high affinity for skeletal muscles, and the brain (Figure 4) (Dubey 1998).

While the structural differences between tachyzoites and bradyzoites are subtle, we can still tell them apart (Table 1). Bradyzoites contain a larger number of amylopectin granules in their cytoplasm. Periodic acid –Schiff stain is used to detect cytoplasmic polysaccharides such as amylopectin. Tachyzoite nuclei are centrally located, unlike the bradyzoites that have them further down the posterior end. The bradyzoites are less metabolically active than the tachyzoites, and contain no lipid bodies as opposed to tachyzoites. Even though bradyzoites are capable of replication by endodyogeny like tachyzoites, they do it at a much slower rate. While tachyzoites are the hallmark of the acute infection, the bradyzoites are the cyst stages characterizing the chronic phase of the infection (Dubey, 1998).

Furthermore, the switch between these stages highly reflects the progress of toxoplasmosis between its acute and chronic phases, and is tightly governed by the host immune response (Dubey, 1998).

| Tachyzoites | Bradyzoites |
|--|--|
| slender crescent shaped | more slender |
| nucleus more central | nuclues situated towards the posterior |
| labyrinthine rhoptries | electron dense rhoptries |
| usually no amylopectin granules | contain several amylopectin granules |
| more susceptible to destruction by proteolytic enzymes | less susceptible to destruction by proteolytic enzymes |
| | |

Table 1. Differences between tachyzoite and bradyzoite stages of *Toxoplasma gondii*

As early as 1956, Frenkel showed through conducting experiments on hamsters chronically infected with *T. gondii* that not only a transition from the tachyzoite stage to the bradyzoite stage was possible, but that reactivation following cyst rupture and transition from the bradyzoite stage back to the tachyzoite stage occurs in cases of immunosuppression (Frenkel, 1957). This was later confirmed in immunosuppressed human patients (Figure 5).




Figure 5. Section of the cerebrum of a patient with AIDS. Dubey et al. (Clin. Microbiol. Rev. April 1998vol. 11 no. 2 267-299)

E. Life Cycle

T. gondii has a complex life cycle, harboring a sexual stage in the primary or final host, the Felidae, and an asexual stage in the secondary or intermediate host, including humans (Figure 6). The sexual stage of the life cycle starts when a domesticated house cat, ingests by carnivorousism the parasite mostly in its bradyzoite stage, bradyzoites are liberated and reach the intestines of the cat, where they invade the enterocytes and establish their sexual cycle. Merozoites are produced by schizogony, mature and develop into gametocytes, then gametes. After fertilization of a macrogamete by a microgamete, a zygote is formed in the intestinal lining cells of the infected feline definite host. Intestinal epithelial cells then rupture and oocysts are shed into the intestinal lumen as immature oocysts within 3-7 days following ingestion of the infected prey. Upon defecation, unsporulated oocysts are released in nature where sporulation occurs. After 4 to 10 days post excretion and under appropriate environmental conditions, a sporulated oocyst containing 2 sporocysts harboring 4 sporozoites each forms and represents the infective form, ready to start a new cycle (J. Dubey, 1998).

Upon oral ingestion of food contaminated with sporulated oocysts from the environment by any warm-blooded animal, the asexual or intermediate life cycle begins (Figure 6). The digestive enzymes of the gastro-intestinal tract lead to the liberation of sporozoites which will rapidly transform into tachyzoites in the blood. These tachyzoites are responsible for the acute phase of infection and are capable of invading any nucleated cell as well as crossing the blood-placental barrier. They hijack dendritic cells and macrophages recruited to the site of infection and use them as Trojan horses to disseminate to distal sites (Lambert, Henrik, et al., 2006). Approximately 5 days after

ingestion, and under the immune response, these tachyzoites transformed into bradyzoites that encyst in the brain and skeletal muscles. These formed tissue cysts stay dormant as long as the host is immunocompetent (J. P. Dubey et al., 1998) (J. P. Dubey, 2007). In immunosuppressed patients, these bradyzoites may become life threatening if they reactivate back into tachyzoites (Mele et al. 2002).




Figure 6. *Toxoplasma gondii* life cycle (Robert-Gangneux, and Dardé, Clin. Microbiol. Rev. 2012)

F. **Epidemiology and Transmission**

T. gondii has been described in 350 species so far (Robert-Gangneux et al., 2012). It is thought that around one third of the world's human population is infected with *Toxoplasma gondii* (Dubey et al., 2009). Depending on the environmental conditions of any specific area seroprevalence can range from zero to 100% (Tenter et al., 2000). Seroprevalence increases in climates that are tropical and decreases in dry and cold climates. In Lebanon, seroprevalence determined on 1371 sera from hospital laboratories and 2145 sera from private laboratories were 55% and 67%, respectively based on serum IgG levels of patients (Bouhamdan et al., 2010).

The high prevalence of *Toxoplasma gondii* is partly due to its prolonged ability to be transmitted from host to host in various forms depending on the circumstances of transmission (Figure 7). Ingestion of intermediate host meat contaminated with *T. gondii* tissue bradyzoite cysts seems to be the most common mode of transmission (Cook et al., 2000).

On the other hand, oocysts shed as unsporulated in cats' feces at first, sporulate later to become infective and represent the other way of the parasite transmission. Despite that cats' shedding of oocysts being of short duration, 2 to 3 weeks, (Dabritz et al., 2007) (Dumètre et al., 2003), nevertheless, a single cat can shed over a 100 million oocysts (Gangneux et al., 2012), which makes the environmental burden very high (Dubey et al., 2011).

Moreover, in primo-infected pregnant women, *T. gondii* is vertically transmitted in its tachyzoite through the placental barrier to the fetus (Wong and Remington, 1994). As pregnancy progresses, the placenta becomes more permissive to

the passage of tachyzoites replicating at the placental site, thus the risk of congenital toxoplasmosis increases from around 25% during the first trimester to 65% during the third trimester. However, severity of the congenital disease on the fetus is inversely related to the age of gestation at which the gravid mother acquires the parasite (McAuley, 2014).




Figure 7. Transmission of *T. gondii*. Worth et al. Trends in parasitology 29.4 (2013): 150-155.

G. *Toxoplasma gondii* Pathogenesis

The type and severity of diseases caused by *T. gondii* vary according to the immunological state of the host as well as the type of the parasitic strain.

1. In immunocompetent patients:

It has been believed that only 20% of immunocompetent individuals that acquire the parasite exhibit signs of illness, mainly presented in the form of lymphadenopathy, and in rarer instances as chorioretinitis, myocarditis, or polymyositis (Montoya, 2002). Nowadays, scientific discoveries point out that the parasite might be associated with increased risk of psychiatric disorders in cases previously assumed asymptomatic carriers. For instance, *T. gondii* seroprevalence has been examined in association with disorders such as mania, schizophrenia, and bipolar disorder. An association has been found between these disorders and seropositivity (Fuller and Yolken, 2003) (Hamdani et al., 2013) (Dickerson et al., 2014).

2. In immunosuppressed patients

T. gondii infection in immunocompromised patients can be life-threatening. The disease outcome is the result of reactivation of bradyzoites back to the fast replicating tachyzoites. This mainly manifests as toxoplasmic encephalitis (TE) that can lead to serious complications such as dementia, seizures, and possibly death. Patients with AIDs who are harboring the parasite usually start showing signs of TE when their CD4⁺ T cell counts falls under 100 cells/ μ l (Robert-Gangneux and Dardé, 2012). Treatment with highly active antiretroviral therapy (HAART) received by HIV

patients results in a dramatic drop in the development of TE (Abgrall et al., 2001). Furthermore, other manifestations of toxoplasmosis can appear due to the reactivation of a latent infection and include chorioretinitis, pneumonitis, myocarditis and others which are less frequent than TE (Table 2).

| Common Symptoms | Rare Symptoms |
|-----------------|-----------------|
| Encephalitis | Fever |
| Lymphadenopathy | Chorioretinitis |
| Pneumonitis | Splenomegaly |
| Myocarditis | Ploymyositis |
| Hepatitis | |

Table 2. Symptoms associated with the reactivation of toxoplasmosis in immunocompromised patients

3. In primo-infected pregnant women

Primo-infection of seronegative pregnant women with *T. gondii* leads to congenital toxoplasmosis. The severity of the infection on the fetus depends on the pregnancy trimester during which infection occurs (Desmonts and Jacques, 1974). Virulence is higher during the first two semesters of the pregnancy and can lead to severe congenital abnormalities and even intrauterine fetal death. Congenital toxoplasmosis can present itself in a wide range of manifestations, involving several organs and resulting in disease entities such as myocarditis, hepatosplenomegaly, pneumonitis (McAuley, 2014), hearing loss (Salviz et al., 2013) and others. The symptoms are mostly pertaining to the CNS of the infant. The classic triad of congenital toxoplasmosis is chorioretinitis, intracranial calcifications, and hydrocephalus (McAuley, 2014). Other CNS symptoms include microcephaly (Schmidt et al., 2006). Even though most infants, around 85%, exhibit symptoms directly after birth or within the first month (Bollani et al., 2013) and may continue to do so until 5 years.

H. Significance of *T. gondii* as an Experimental Model

T. gondii is the major and tractable experimental model for the study of apicomplexan biology and parasitism because of many advantages: its different pathogenic stages are easily cultured, propagated and quantitated *in vitro*. Furthermore, *Toxoplasma* genome is fully sequenced and allows all possible manipulations/predictions of genes. More importantly, mouse models for studying host/parasite interactions during infection, as well as latent versus acute phases are well documented. Moreover, *T. gondii* can be easily crossed and transfected both transiently and stably *in vitro* and in diverse animal models (Hager et al., 1999) (Kim & Weiss,

2004). Finally, *T. gondii* is a very malleable model for establishing knock-outs, conditional knock-outs and more recently, the Crispr-Cas9 technology has been successful in this parasite (Shen et al., 2014). This genetic flexibility allows a better understanding of gene functions in *Toxoplasma* in particular, and in other related apicomplexans, namely *Plasmodium*, *Eimeria* and others.

I. *Toxoplasma gondii* Surface Markers

1. *Tachyzoite Surface Antigen-1 (SAG-1)*

Toxoplasma gondii displays a wide array of surface antigens that are mostly stage specific (Manger et al., 1998) and each having a role in adhesion, cell penetration, or parasite survival through evasion of host cell immune response (Carruthers and Boothroyd, 2007) (Cong et al., 2013). The surface of the parasite is dominated by a Surface Antigen Glycoprotein-1, called SAG-1, belonging to a family of Glycosyl-Phosphatidyl-Inositol (GPI)-linked proteins of which over 160 members have been discovered and that bifurcate into 2 branches the SAG-1-sequence like branch and the SAG-2-sequence like branch (Crawford et al., 2009) (Cong et al., 2013). Being the most prominent surface antigen of the parasite's tachyzoite stage, SAG-1 plays a major antigenic immune-stimulatory role, mainly during the acute phase of the infection. It is an important target for both the humoral and the cell-mediated acute immune response (Wang and Yin, 2014). The cell-mediated immune response, however, is the dominant one in the case of *T. gondii* infection and SAG-1-specific CD8+ T cells can be observed in mice as an aftermath of acute toxoplasmosis (Wang and Yin, 2014).

2. The Bradyzoite Antigen-1 (BAG-1) marker

Among many bradyzoite markers (Table 3), specific heat shock proteins were characterized, among which is the Bradyoite Antigen-1 BAG-1. BAG-1 is expressed by the *hsp30/bag1* gene. It has homology to small heat shock proteins and therefore has also been called hsp30 (Bohne et al., 1995; Parmley et al., 1995). Both BAG-1 mRNA and protein (a 28 kDa cytoplasmic antigen) are up-regulated during bradyzoite formation, suggesting transcriptional regulation of its expression. In fact, BAG-1 is one of the most abundant bradyzoite specific genes found in the *T. gondii* bradyzoite. Its expression is detectable within 24 hours post stress induction on *T. gondii* parasites and hence its characterization as a stress respondent would naturally accompany the transition from tachyzoites to bradyzoites under stress conditions (Knoll et al., 2014).

3. The Bradyzoite Markers: p36, p34, p21 and p18

For quite a long while, research in the field of toxoplasmosis remained centered around the readily available tachyzoite developmental stage. However with the emerging interest in stage conversion, many studies were directed towards the characterization of stage specific developmentally regulated molecules. Antibodies against stage-specific markers for bradyzoites and tachyzoites were developed (Tomavo et al., 1991). These antibodies were selected by differential immunofluorescence assays aiming to isolate them from hybridomas produced against these organisms. Antigenically reactive markers to these antibodies were found on human isolates of *T. gondii*, as well as on laboratory strain bradyzoites obtained from either brain cysts or *in vitro*-grown parasites (Tomavo et al., 1991). These monoclonal antibodies are T₈4A₁₂

recognizing a 36 kDa protein called P36, T₈ 2C₂ recognizing a 34 kDa protein called P34, T₈ 4G₁₀ recognizing a 21 kDa protein called P21 and T₈ 3B₁ recognizing an 18 kDa protein called P18 (Tomavo et al., 1991). These proteins represent four pellicular antigens, three of which are exposed on the surface of the organism (Tomavo et al., 1991).

4. The bradyzoite marker SAG-4 or P18:

Among the three bradyzoite markers (P34, P21 and P18), only the gene encoding for P18 was sequenced and published (Ödberg-Ferragut et al., 1996). Real time using P18-specific primers demonstrated the stage specific expression of this gene only in the bradyzoites transcripts. The sequenced gene showed no substantial homology to any of the known genes, hence it was recognized as novel and in accordance to the nomenclature proposed by Sibley, the *P18* gene was given the name *SAG4* (Ödberg-Ferragut et al., 1996). Insights towards a functional characterization of P18 were still absent until our laboratory established the Knockout of *P18* in the Pru $\Delta KU80$ type II strain (PRU $\Delta KU80\Delta P18$).

| Name of Antigen | Size in kDa | Localization | Proposed Function | Cloned <i>T. gondii</i> database No. |
|-------------------|-------------|--------------|--------------------------|--------------------------------------|
| BAG1 (hsp30/BAG5) | 28 | Cytoplasm | Small heat-shock protein | TGME49_259020 |
| BSR4 (p36) | 36 | Surface | SAG1 family Ag | TGME49_320180 |
| SAG4 (p18) | 18 | Surface | Under Investigation | TGME49_280570 |
| p21 | 21 | Surface | Surface Ag | N/A |
| p34 | | Surface | N/A | N/A |

Table 3. Common Bradyzoite Markers

J. *Toxoplasma gondii* Strains

T. gondii displays very low genetic divergence and its strains can be grouped into 3 stable clonal lineages or major genotypes (called types I, II, and III) (Table 4). These lineages only exhibit about 1-2% genomic differences (Robert-Gangneux, 2012). While type I strain has been demonstrated to be the most virulent in mice resulting in parasitemia and ultimately death, type II strain has a higher capacity for forming tissue cysts in the brain and is more readily reactivated in cases of immunosuppression. Type III strain is considered avirulent in mice and is found almost as frequently in animals as type II. In humans, the most common strain remains type II and is the most frequently isolate from cases of immunosuppressed individuals as well as those with congenital toxoplasmosis (Howe and Sibley, 1995).

| Strain | Characteristics | Examples |
|--------|--|----------------------|
| I | Most virulent, least common strain in animals. | RH strain |
| II | Less virulent, asymptomatic to mild disease in immunocompetent hosts, high capacity for cyst formation, most common in animals and humans. | ME49 and PRU strains |
| III | Less virulent, asymptomatic to mild disease in immunocompetent hosts, common in animals, least common in humans. | NED strain |

Table 4. The 3 common lineages of *T. gondii*

K. A New genetic model of type II strains: PRU Δ KU80

Double Strand Break (DSB) repair in most eukaryotes occurs primarily *via* two different recombination pathways (Haber, 2000). The homologous recombination pathways repair a DSB using mechanisms that recognize highly homologous DNA sequences, while the non-homologous end-joining (NHEJ) pathway does not rely on DNA sequence homology. Instead, NHEJ involves direct ligation of the ends of broken DNA strands. KU70 and KU80 proteins form a heterodimer that tightly binds the DNA ends at the DSB, an early and essential step of NHEJ (Walker et al., 2001; Wu et al., 2008). Many eukaryotes preferentially use the NHEJ pathway to repair a DSB, and exogenous targeting DNA can be integrated anywhere into the genome independent of DNA sequence homology (Haber, 2000). The NHEJ pathway also appears to be preferentially used by *T. gondii* based on the high rates of non-homologous recombination and low gene targeting frequencies observed experimentally (Donald & Roos, 1998; Fox & Bzik, 2002; Gubbels et al., 2008; Morrissette et al., 1997). Because KU80 has been implicated in the DNA double-strand break repair mechanism associated with the DNA kinase repair model, by binding to the free ends of the broken DNA strands (Taccioli et al., 1994), Fox et al. decided to develop *KU80* knockouts (Δ *KU80*) in type II *T. gondii* (Fox et al., 2009), making it easier to further genetically manipulate this strain of the parasite by eliminating the *KU80* housekeeping gene. These Δ *KU80* are void of the dominant pathway mediating random integration of targeting episomes and hence allow for a 97% increase in efficiency of double-crossover homologous recombination at targeted loci (Fox et al., 2009). Fox et al. targeted the deletion of four parasite antigen genes (*GRA4*, *GRA6*, *ROP7*, and *tgd057*) that encode characterized CD8⁺ T cell epitopes that elicit corresponding antigen-specific

CD8⁺ T cell populations associated with control of infection (Fox et al., 2011), thus highlighting the importance and value of such knock-outs.

1. *PRUΔKU80ΔP18*:

Using the *PRUΔKU80* that has been shown to be very efficient to knock out genes, especially those in type II stains, our laboratory investigated the function of the bradyzoite surface marker *P18*. Our laboratory has used the vector (P2854) containing the selectable marker cassette hypoxanthine-xanthine-guanine-phosphoribosyl-transferase (HXGPRT) and cloned the 5' and 3' flanking regions of *P18*. This vector was introduced by electroporation to the *PRUΔKU80* strain which favors its integration by double crossing over and homologous recombination. Our laboratory successfully generated and cloned the *PRUΔKU80ΔP18* knock-out parasites and investigated their phenotype *in vivo* (Tawil, Diss. 2014). Furthermore, deleting *P18* leads to the formation of more bradyzoite cysts in the brains of Swiss Webster mice. However, these bradyzoites reactivate much later than the wild type strain (Tawil, Diss. 2014). In more details, after induction of immunosuppression using dexamethasone, mice had better survival capacity when then were infected with the *PRUΔKU80ΔP18*. Since the host immune response is the key driver of the back and forth switch between tachyzoite and bradyzoite stages, additional studies investigating the host immunological response upon *P18* deletion were needed, underlying the importance of the current study. This will allow a better understanding on how *P18* expression affects the host immune response and therefore the cyst burden and the disease outcome.

L. Immunology of *Toxoplasma gondii*

1. Introduction:

The success of the parasite resides in its ability to establish a balance within the host immune response, such that the infection does not lead to the death of the host, and by extension that of the parasite, but allows it to persist in such a way that it increases its chances of propagating in nature. This can happen only with the delicate balance between an immune response strong enough to drive the parasite into latency but weak enough not to cause permanent tissue damage or even death to the host.

With the aid of its surface antigens and secretory proteins, *T. gondii* starts invading host cells and creating a desirable environment for its long-term survival within parasitophorous vacuoles. The role of effector proteins secreted during the establishment of the host-cell infections are still being studied and are becoming better understood today in light of their effect in manipulating the medium of the host cell and its pro-inflammatory and anti-inflammatory processes. Among these initial modulators are rhoptries and dense granular proteins.

T. gondii, like other microorganisms, possesses a variety of molecules foreign to the host's body known as Pathogen Associated Molecular Patterns (PAMP). These PAMPs can be recognized by Toll-like receptors on the surface of a wide variety of host cells. The interaction between PAMPs and TLRs is one of the major triggers of the innate immune response (Takeda, Tsuneyasu, and Akira, 2003). In this regard, *T. gondii* can trigger cytokine secretion by immune cells through either myeloid differentiation factor 88 (MyD88) dependent or MyD88 independent signaling pathways (Figure 8). MyD88 is an important adapter molecule in the cellular signaling

cascade initiated by PAMP-TLR interaction that triggers cellular cytokine secretion (Scanga et al., 2002).




Figure 8. Host cell responses that can be modulated by *Toxoplasma gondii* (Melo et al., Trends in parasitology 2011)

T. gondii possesses a range of molecules that behave as PAMPs one of which is cyclophilin which is a proflin-like molecule that interacts with TLR-11 on macrophages and dendritic cells prompting them to secrete IL-12 (Figure 9) (Melo et al., 2011).




Figure 9. Effector mechanisms in Type II toxoplasmosis (Melo et al., Trends in parasitology 2011)

T. gondii stimulates the innate immune response with the ultimate player being NO (NO) which has a direct highly toxic effect on the parasite, interacting with it through the parasitophorous vacuole, as well as the ability to control the acute stage of the infection through triggering its switch from the tachyzoite to the bradyzoite stages. At the basis of this switch possibly lies parasitic deprivation of L-arginine, required for the metabolism of the parasite (Figure 10). Inducible NO synthase enzyme promotes the synthesis of NO (NO) from host cell L-arginine leading to its depletion (Melo et al., 2011).

NO is released by macrophage under the effect of another important cytokine, IFN- γ , which in turn is released by cells stimulated with IL-12. So while these 3 cytokines play the major role in inducing an immune response sufficient to control an acute infection, and keep it under control, IL-10 is the major anti-inflammatory cytokine that keeps the immune response in check (Munoz, Liesenfeld, and Heimesaat, 2011).




Figure 10. Effector mechanisms of IFN γ -mediated parasite elimination in infected cells. Yarovinsky, *Nature Reviews Immunology* 14.2 (2014): 109-121.

2. Host immune Response during acute toxoplasmosis in Type II Toxoplasma gondii infection


After ingestion of tissues containing viable bradyzoites within cysts or of sporozoites inside oocysts, the parasite is released in the alimentary tract and reaches the intestinal cells which it then starts invading to initiate replication in the form of tachyzoites. Enterocytes start secreting chemotactic factors such as monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory proteins and others as well as interleukins such as IL-12, IL-15, to a lesser extent IL-10 and others (Miller et al., 2009).

GRA-15, a dense granular protein in type II *Toxoplasma gondii* activates the NF- κ B inside the infected host cells, macrophages and dendritic cells, further stimulating the release of IL-12 as well as the pro-inflammatory cytokine IL-1 β which in turn cause an overproduction of IFN- γ by T helper and Natural Killer (NK) cells (Figure 9). (Melo et al., 2011)

IL-12 is an important cytokine that activates different cells of the immune response into secreting IFN- γ , such as neutrophils and NK cells and T lymphocytes (Gazzinelli et al., 1994) (Hunter et al., 1994). While IL-15 is directed at NK cells also leading to stimulation of these cells to secrete IFN- γ . The released chemokines then attract firstly neutrophils to the site of infection and secondly macrophages and dendritic cells that are hijacked by the parasite and used as Trojan horses in order to disseminate from the primary site of infection to the rest of the body (Lambert et al., 2009) (Ueno and Lodoen, 2015).

In cases of intraperitoneal injection of mice with tachyzoites, it usually takes around 6-8 hours for the neutrophils to arrive at the site of the infection, under the effect

of chemokines released from infected necrotized tissues (Bliss, et al., 1999). Upon interaction with the parasite through their Toll Like Receptors (TLRs), these cells start secreting cytokines such as IL-12, TNF- α , IFN- γ , and others (Bennouna et al., 2003) (Denkers et al., 2004) (Bliss et al., 1999) (Figure 8). When macrophages and dendritic cells arrive, some are hijacked by the parasites, while some of them interact as well with the parasite through their TLRs to release IL-12 (Melo et al., 2011). This interaction occurs through their surface TLR-2 and TLR-4 with parasitic GPI and LPS respectively as well as TLR-11 which interacts with parasitic profilin (Yarovinsky, 2008)(Kumar et al., 2009) (Figure 11). The release of IL-12 activates T lymphocyte proliferation and polarizes the immune system towards a strong Th-1 response (Denkers et al., 2004). Dendritic cells in addition to being crucial sources of IL-12 (Miller et al., 2009) are also APCs, they migrate to secondary lymphoid tissues and present *T. gondii* antigens to T lymphocytes priming them and leading to their activation with the production of IL-12 (Tait and Hunter, 2009). Though T lymphocytes do play an important role controlling the infection through their cytotoxic effect on infected cells (Montoya et al., 1996) especially cytotoxic CD8⁺ T cells by secretion of perforin and lysis of the infected cells (Blanchard, Dunay, and D. Schlüter, 2015), the major role of T lymphocytes is demonstrated in the secretion of IFN- γ (Figure 11), especially in the setting of the brain (Munoz, Liesenfeld, and Heimesaat, 2011) (Parlog, Schlüter, and Dunay, 2015) (Denkers and Gazzinelli, 1998) which stimulates the release of NO by macrophages and microglia, as well as TNF- α , and other proinflammatory cytokines such as IL-1 β and IL-6 (Weiss and Kami, 2011).



Nature Reviews | Immunology

Figure 11. Interferon- γ (IFN γ) is crucial for survival during *Toxoplasma gondii* infection. (Yarovinsky et al., Nature Reviews Immunology 2014).

It is noteworthy to mention that the role played by IFN- γ secreted from T lymphocytes and NK cells extends beyond stimulating the secretion of NO as it also stimulates the expression of indoleamine 2,3-dioxygenase (IDO) which leads to depletion of host cell tryptophane, an essential requirement for *T. gondii* metabolism and survival pushing the parasite into a state of “starvation”, an inhibitory protein. Adding to that it stimulates the expression of immunity-related GTPases (IRGs) and guanylate-binding proteins (GBPs) (Figure 10). The IRGs and GBPs play a role in the destruction of the parasitophorous vacuole, the organelle engulfing intracellular parasites and protecting them from destruction through resisting binding to intracellular lysosomes (Melo, Jensen and Saeij, 2011).

In addition to the above-mentioned inflammatory process, there should exist an anti-inflammatory process through which the parasite can ensure the survival of the host. This can be achieved by allowing the host to avoid excessive tissue necrosis and damage as a result of inflammasome-inducing pro-inflammatory cytokines (Melo et al.,

2011). This is especially important at the site of the brain, and mice deficient in IL-10 succumb to death (Wilson et al., 2005). One of the major players in down-regulating the immune response, thus protecting the host and the parasite alike, is IL-10 (Figure 12). The major source of IL-10 remains the same IFN γ -secreting Th1 CD4⁺ lymphocytes (Melo et al., 2011).




Figure 12. IL 10, an important immunosuppressor (Aliberti et al., Nature Reviews Immunology 2005)

3. *Host brain immune Response during the chronic phase of toxoplasmosis*

Upon reaching the brain, carried in macrophages and dendritic cells, the parasite is able to establish an infection in all three types of resident brain cell, the neurons, microglia, and astrocytes, in addition to immune cells migrating to the brain as a site of infection (Blanchard et al., 2015) (Figure 13). Neurons, however, act as a safest niche for the successful establishment of chronic infection, possibly due to their diminished ability to process and present antigens, therefore behaving as a safe medium for bradyzoites to hide (Blanchard et al., 2015). MCP-1 secreted by astrocytes serves as a chemoattractant for wandering monocytes to enter the brain (Munoz et al., 2011). Collectively, the parasitic infection in the brain is kept under control by Th-1

proinflammatory cytokines such as IL-1 β and IL-6 secreted by T lymphocytes that have migrated to the brain either through crossing the BBB or as more recently suggested through lymphatics (Louveau et al, 2015), in addition to IFN- γ and TNF- α , that activate IL-12 secreting microglia and macrophages to produce NO (Parlog et al., 2015). Another important sources of brain IFN- γ comes also from NK cells that have just as well migrated to the brain (Blanchard et al., 2015). In addition to IFN- γ , NK cells and CD4⁺ T lymphocytes are important in producing IL-10, which has an important role in dampening the immune response in order to avoid excessive damage by the immune response to the host's tissues (Hunter et al., 1994) (Neyer et al., 1997) (Miller et al., 2008). Infiltrating macrophages have also been found to be a major source of IL-10 in the brain, demonstrating an essential role in inhibiting the effects of excessive inflammation in TE (Wilson et al., 2005). *T. gondii* has also been suggested to mediate the anti-inflammatory effect of IL-10 as a counter-regulatory immune mechanism by hijacking the STAT3 pathway of infected cells (Munoz et al., 2011).




Figure 13. Immune response to *T. gondii* in the infected brain by resident and recruited immune cells. Blanchard et al., *Parasite immunology* 37.3 (2015): 150-158.

In our experiment we decided to focus our investigation on the following cytokines (Table 5), being the major players in the immune response against *T. gondii*.

| Cytokine | Role |
|---------------------|--|
| MCP-1 | chemokines that regulate the recruitment of of monocytes, macrophages, and dendritic cells to the site of infection. Mainly secreted by activated neutrophils and brain astrocytes |
| IL12 | Secreted mainly by macrophages and dendritic cells as well as microglia. Polarizes immune response to Th1 |
| IFN γ | Promotes expression of iNOS and therefore secretion of NO in macrophages and microglia. Main source is activated T and NK cells |
| TNF α | Co-stimulates macrophages with IFN γ to secrete NO |
| IL1 β and IL6 | Pro-inflammatory cytokines secreted mainly by activated T lymphocytes |
| IL10 | Anti-inflammatory cytokine that downregulates the immune response. Main source is CD4 ⁺ T lymphocytes |
| iNOS | Inducible nitric oxide synthase enzyme responsible for production of nitric oxide by macrophages and microglia |

Table 5. Summary of important cytokines involved in toxoplasmosis immune response

M. Cytokine Summary

1. NO (NO)

Produced by macrophages and brain microglia through the conversion of L-arginine under the effect of inducible NO synthase (iNOS) enzyme (Aktan, 2004). It has been found to be one of the most effective element of the innate immune response in the control of *T. gondii* infection (Suzuki et al., 2007). Its role exceeds direct parasitic destruction through its microbicidal effect into triggering conversion of tachyzoites into

bradyzoites, essentially through depriving the intracellular parasites from fulfilling their L-arginine metabolic needs (Weiss and Kami, 2011).

2. *IL-12*

Is supplied mainly by dendritic cells, in addition to macrophages and brain microglia and others such as neutrophils (Gazzinelli et al., 1994) (Bliss, Zhang, and Denkers, 1999). It is secreted in response to parasitic PAMPs interactions with TLRs on these cells (Yarovinsky, 2008) and is a participant in the polarization of the immune response to a strong Th-1 response (Miller et al., 2009) as well as for inducing IFN- γ secretion by T lymphocytes and NK cells (Suzuki et al., 2007).

3. *IFN- γ*

Is possibly one of the most studied effectors of the immune response to *T. gondii* due to its essential role in stimulating the production of NO from macrophages and microglia (Pelloux, 1996) (Yarovinsky, 2014). IFN- γ is mostly secreted by NK cells and T lymphocytes (Suzuki et al., 2007) (Munoz, Liesenfeld, and Heimesaat, 2011).

4. *TNF- α*

Secreted by neutrophils and T lymphocytes, it is responsible for co-stimulating macrophages to produce NO along with IFN- γ . It has an important protective role against the development of toxoplasmic encephalitis in the infected host (Deckert-Schlüter, 1998).

5. *IL-1 β* and *IL-6*

These proinflammatory cytokines are mainly secreted by CD4⁺ T lymphocytes systemically and within the brain in the presence of toxoplasmosis (Naginei, Detrick, and Hooks, 2000). They are pyrogenic and regulate the acute phase of reaction of the immune response (Chao et al., 1994). IL-6 has been found to play a role in controlling the parasite burden as well as the amount of cysts found in the brain of the infected host (Jebbari et al., 1996). Furthermore, IL-1 β was shown to be required for stimulating the production of IFN- γ by IL-12 stimulated NK cells (Hunter, Chizzonite, and Remington, 1995).

6. *IL-10*

IL-10, being an immunosuppressant is crucial for the control of the pro-inflammatory response directed at toxoplasmosis (Khan, Tadashi, Kasper, 1995). In cases of IL-10 deficiency, murine hosts have been found to succumb to death to extensive inflammation and necrosis (Gazzinelli, 1996).

7. *MCP-1/CCL-2*

MCP-1 is one of the most important chemokines that regulate the recruitment of monocytes, macrophages, and dendritic cells to the site of infection. Along with other chemokines, it is secreted in *T. gondii* infections primarily by activated neutrophils (Del Rio et al., 2004) and by astrocytes in the brain.

CHAPTER II

Materials and methods

A. Experimental Design

The following diagram represents the timeline of our experiment including major hallmarks (Figure 14). On Day 0, mice were injected with either strain of *Toxoplasma gondii*. On Day 4, all mice were provided with sulfadiazine in their drinking water in order to help them survive the acute phase of toxoplasmosis. On Day 7, we obtained blood samples from the periorbital sinus of each mouse in order to verify the infection using the sera in the western blot technique. We started sacrificing the mice on day 14 post-infection, 4 from the group infected with the *P18* knock-out strain and 4 infected with the original strain. We repeated these sacrifices in 7-day-intervals.




Figure 14. Experiment Timeline

B. Ethical Statement

The Institutional Animal Care and Utilization Committee of the American University of Beirut approved the murine protocols (#15-10-350). The mice were subjected to a 12-hour light and dark cycles. Mice were anesthetized using isoflurane and sacrificed by cervical dislocation.

C. Maintenance of Parasites in Human Foreskin Fibroblasts (HFF) culture:

Toxoplasma gondii tachyzoites from type II strains Pru Δ KU80 (kindly provided by Drs Maryse Lebrun and Jean Francois Dubremetz from France) and Pru Δ KU80 Δ P18 (generated in our lab), were maintained by serial passages in Human Foreskin Fibroblasts (HFFs) grown in Dulbecco's modified Eagle medium (DMEM) (Lonza) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine 1% penicillin –streptomycin and kanamycin (Lonza).

Parasites were quantified using a haemocytometer. And calculations were performed to acquire 250 tachyzoites per 200 μ l of PBS per injection per mouse.

D. The C57BL/6 mouse model

32 females C57BL/6 mice of 10-12 weeks old were used in our experiments. Mice were divided into two groups and were intraperitoneally infected with 250 parasites of either Pru Δ KU80 or Pru Δ KU80 Δ P18 parasites. At day 4 post infection (post-infection), sulfadiazine was added to the drinking water at the concentration of 300 mg/L for two weeks of the experimental duration. Sulfadiazine

slows the rate of replication of tachyzoites and helps the mice to overcome death that may occur during the acute phase of infection thus switching into the chronic phase (Figure 14). 7 days post-infection, blood was sampled using retro-orbital puncture and blood was obtained from the medial cathenus of each injected mouse to verify acute infection by western blotting (section below). Seropositive mice against the acute infection were sacrificed on a weekly basis starting day 14 post-infection Brains were collected to quantify parasite load and the corresponding elicited immune responses. Brains were homogenized using (BioSpec) and were used for RNA extraction.

E. Verification of Infection by Western Blot

On day 7 post-infection, approximately 1 ml of blood from the retro-orbital sinus of each mouse were collected.

PRU Δ KU80 tachyzoites were obtained from a culture T25 flask for boiling in Laemmli SDS-PAGE sample buffer and running on previously prepared 12% polyacrylamide gels covered with 4% stacking gel in order to separate the protein bands, which were then transferred onto a nitrocellulose membrane overnight using a BioRad transfer unit at 30V.

5% non-fat dry milk in wash buffer composed of 15 mM Tris HCL (pH 8), 150 mM NaCl and 0.05% Tween 20 was utilized for blocking for 1 hour. Blood samples obtained from mice were centrifuged at 13,000 r.p.m for 15 min and 10 μ l of obtained sera were used in 1 ml 5% non-fat milk dissolved in wash buffer to incubate the strips and reveal seropositivity. Incubation was carried out overnight at 4⁰C. The strips were then washed and incubated with anti-mouse HRP (Horseradish peroxidase)-conjugated

secondary antibodies (1:5000 dilution, Santa cruz, sc-2031, lot: B2212). A luminol chemiluminescent (Santa cruz, sc-048) was used to confirm seropositivity. This chemiluminescent substrate binds to the secondary antibodies and producing autoradiography detectable luminescence.

F. Brain Harvesting and RNA Extraction

14 days post-infection., we started sacrificing mice after deep anesthesia with isoflurane followed by cervical dislocation and their brains were harvested for mRNA extraction.

500µl of TRIZOL[®] were added to each brain followed by homogenization and the addition of another 500µl of TRIZOL[®]. The samples were then left for 5 minutes at room temperature. 200µl of chloroform were then added to the samples which were vortexed for 1 minute followed by spinning at 15,000g for 10 minutes at 4^oC.

The upper phase of the solution was then placed in new Eppendorf tubes and 500µl of isopropanol were added to each tube, followed by another spin at 15,000g for 10 minutes at 4^oC.

The supernatant this time was discarded, the pellet air-dried, and resuspended in RNase-free H₂O. The absorbance was measured at 260nm using a nano drop spectrophotometer (ND-1000).

G. cDNA synthesis

cDNA synthesis kit provided by Thermo (#K1622) was utilized and the protocol was followed according to the manufacturer's recommendations. 1 μ l of random primer was added to each sample containing 2 μ g of extracted mRNA diluted in 11 μ l RNase-free H₂O and the samples were incubated for 5 minutes at 65^oC.

This was followed by the addition of 7 μ l of a master mix to each sample, containing 4 μ l of 5x Reaction Buffer, 1 μ l of Ribolock RNase Inhibitor (20U/ μ l), and 2 μ l of 10 Mm dNTP Mix. The 20 μ l mixture was pulse spun for 30 seconds and incubated in a PCR machine at 25^oC for 5 minutes followed by 60 minutes at 42^oC and finally for 5 minutes at 70^oC before it was stopped at 4^oC.

The following table summarizes the contents of the reaction:

| | |
|---|------------|
| RNase/DNase free water containing 5 μ g of template RNA | 11 μ L |
| Random Primers | 1 μ L |
| 5X Reaction Buffer | 4 μ L |
| Ribolock RNase Inhibitor(20U/ μ l) | 1 μ L |
| 10 Mm dNTP Mix | 2 μ L |
| RevertAid M-MuLV RT (200U/ μ l) | 1 μ L |
| Total Volume | 20 μ L |

Table 6. cDNA components utilized for synthesis and respective volumes

H. Quantitative Real-Time Polymerase Chain Reaction (qRt-PCR)

qRT-PCR was performed using SYBR Green as dye and a BIORAD machine (CFX96 Optics Module, Serial No. 785BR04788). Glyceraldehyde-3-Phosphate dehydrogenase (GAPDH) was used as the reference gene for normalization of Ct values. Mouse GAPDH primers (Table 7) were used to detect and quantify the GAPDH transcription levels.

150 ng of cDNA (1.5 μ l) was used for the mixture of each sample, then we added 5 μ l of SYBR Green dye, 0.25 μ l respective forward primer (15 μ M) and 0.25 μ l respective reverse primer (15 μ M) along with 4.5 μ l RNase-free H₂O. Total volume of each sample became 11.5 μ l.

Procedure protocol involved a DNA denaturation cycle at 95⁰C for 3 minutes followed by 35 cycles of denaturation at 95⁰C for 15 seconds, annealing for 60 seconds at a primer-dependent temperature and extension at 72⁰C for 30 seconds. Each sample was quantified in duplicate reactions.

Relative quantification was performed on the results obtained from Rt-PCR. This is mainly done by calculating Δ Ct (Ct (Cytokine) – Ct(GAPDH)). Then $\Delta\Delta$ Ct was calculated as Δ Ct (Cytokine in infected mice)– Δ Ct (Cytokine in mice infected with PRU Δ KU80 on day 14 post-infection). We proceeded according to the Livak method ($2^{-\Delta\Delta$ Ct}) to obtain the percentage of expression (Schmittgen and Livak, 2008).

| Primer | Sequence 5'→3' |
|------------------------------------|------------------------------------|
| Mouse GAPDH Forward Primer | 5'-CATggCCTTCCgTgTTCCTA-3' |
| Mouse GAPDH Reverse Primer | 5'-CCTgCTTCACCACCTTCTTgAT-3' |
| Mouse BAG-1 Forward Primer | 5'-gCggAgAAAgTggACgATgATgg-3' |
| Mouse BAG-1 Reverse Primer | 5'-gTCgggCTTgTAATTACTCggg-3' |
| Mouse iNOS Forward Primer | 5'-CTT TGC CAC GGA CGA GAC-3' |
| Mouse iNOS Reverse Primer | 5'-TCA TTG TAC TCT GAG GGC TGAC-3' |
| Mouse IL-12 Forward Primer | 5'-TCA AACCCAG ACC CAC CGA A-3' |
| Mouse IL-12 Reverse Primer | 5'-GCT GACCTC CAC CTG CTG A-3' |
| Mouse IL-10 Forward Primer | 5'- GTG ATGCC CAA GCT GAG A-3' |
| Mouse IL-10 Reverse Primer | 5'-CAC GGC CTT GCT CTT GTT TT-3' |
| Mouse IFN- γ Forward Primer | 5'-TgAACgCTACACACTgCATCTTgg-3' |
| Mouse IFN- γ Reverse Primer | 5'-CgACTCCTTTTCCgCTTCCTgAg-3' |
| Mouse TNF- α Forward Primer | 5'-CCA CGT CGT AGC AAA CCA CC-3' |
| Mouse TNF- α Reverse Primer | 5'- GGT GAG GAG CAC GTA GTC GG-3' |
| Mouse IL-6 Forward Primer | 5'-CCA TCC AGT TGC CTT CTT GGG-3' |
| Mouse IL-6 Reverse Primer | 5'-GGT CTG TTG GGA GTG GTA TCCT-3' |
| Mouse IL-1 β Forward Primer | 5'-CATCCAgCTTCAAATCTCgCAg-3' |
| Mouse IL-1 β Reverse Primer | 5'-CACACACCAgCAgCATTATCATC-3' |

Table 7. Primers used in Rt-PCR

CHAPTER III

RESULTS

A. PRU Δ KU80 and PRU Δ KU80 Δ P18 parasites successfully establish acute toxoplasmosis in C57BL/6 mice

After intraperitoneal injection of 250 parasites of the PRU Δ KU80 or PRU Δ KU80 Δ P18 strains in C57BL/6 (16 mice per parasite strain), the mouse immune system mounts a response against the tachyzoites of *T. gondii* clearing some of them and pushing some into the bradyzoite stage that hides in tissue cysts creating the chronic infection later on (Dubey, 1998). During the first week of infection, a resultant of this immune response is the development of antibodies (IgM) directed against parasitic proteins (Robert-Gangneux, and Dardé, 2012). In order to confirm infection in our mice, we collected blood samples on day 7 post-infection from each mouse by eye pricks and sera were used to recognize tachyzoite antigens by western blots, confirming the presence of mouse antibodies and therefore seropositivity. This later is demonstrated by the emergence of a complex banding pattern from antibodies present in the sera of infected mice against tachyzoite proteins. Seronegative mice were excluded from the study.




Figure 15. Verification of *T. gondii* infection by western blot. Each strip corresponds to one mouse's seropositivity test

Upper left group of strips correspond to mice sacrificed on day 14 post-infection. Upper right group of strips correspond to mice sacrificed on day 21 post-infection. Lower left group of strips correspond to mice sacrificed on day 28 post-infection. Lower right group of strips correspond to mice sacrificed on day 35 post-infection. In all gels, from left to right, the first 4 strips belong to sera from mice infected with PRUΔKU80, and the remaining four belong to sera from mice infected with PRUΔKU80ΔP18.

B. C57BL/6 mice infected with PRUΔKU80ΔP18 harbor more cysts than those infected with PRUΔKU80 parasites

BAG-1 is the most abundant bradyzoite marker that has been associated with the latent cyst stages of *T. gondii* specifically as an indicator of chronic infection occurrence in the brains of infected mice (Knoll et al., 2014)

Our lab has previously investigated the effect of knocking out *P18* in the brains of Swiss Webster mice. The results showed that the brains of mice infected with PRUΔKU80ΔP18 harbor more cysts than those infected with PRUΔKU80 (Tawil, Diss. 2014). Since the best animal model to reproduce human TE is the C57BL/6 specially the immune response against it, we started by comparing the capacity of this mouse model of producing cysts in case of the *P18* knock-out. To do so, we first measured the transcription levels of the bradyzoite surface marker BAG-1 in order to insure the

presence of bradyzoites in the brain as well as to compare the capacity of cyst formation in mice infected with the PRU Δ KU80 strain vs. those infected with the respective P18 knock-out strain.

Since the peak of cyst amount is obtained between 3 to 4 weeks post-infection with type II *T. gondii*, we measured the transcription levels of BAG-1 on Day 28 post-infection of mice.




Figure 16. BAG-1 transcription levels measured on day 28 post-infection in the brains of mice infected with PRU Δ KU80 Δ P18 (dotted) and PRU Δ KU80 (black) (n=4 mice each).

Similar to our lab's findings in the Swiss mouse model (Tawil, Diss 2014), a higher level of transcription of BAG-1 was observed in the brains of mice infected with the knock-out strain. This is reflective of a higher number of bradyzoites and therefore a higher cyst burden in the brains of these mice.

C. PRU Δ KU80 Δ P18 recruits more macrophages and dendritic cells than PRU Δ KU80 to the brain of C57BL/6

MCP-1 is one of the most important chemotactic factors responsible for attracting macrophages and dendritic cells (Del Rio et al., 2004), representing the main players in spreading the parasite, in addition to their other roles in the immune response such as the secretion of IL-12 and NO by macrophages (Yarovinsky et al., 2014). Measuring transcription levels of MCP-1 gives us important insights on the number of recruited cells in response to the infection with either strains of parasites.

Our results indicate that over-all MCP-1 transcription levels were higher in the brains of mice infected with the PRU Δ KU80 Δ P18, reaching peak levels on Day 21 (week 3) post-infection (Figure 17), most likely suggesting is a higher number of infected wandering macrophages and dendritic cells reaching the brain.




Figure 17. MCP-1 transcription levels on days 14, 21, 28,35 post-infection Brains of mice infected with PruΔKU80 (black) and those of mice infected with PruΔKU80ΔP18 (diagonal) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

D. **PRUΔKU80ΔP18 induce higher levels of transcription of IL-12 when compared to PRUΔKU80**

As previously mentioned, the major source of IL-12 in *T. gondii* infection in the brain comes from dendritic cells, wandering macrophages and resident microglia that come in contact with the parasitic PAMPs through their TLR receptors (Yarovinsky, 2008).

We assessed whether knocking out *P18* affects IL-12 production. Our results show that higher levels of IL-12 transcription in the brains of mice infected with the PRUΔKU80ΔP18 strain were obtained on days 14 and 21 post-infection, but being significantly higher on day 28 post-infection ($P \leq 0.05$) (Figure 18). This could be due to a higher incidence of interaction between parasites and APCs, supporting the claim

that more parasites are initially being transported to the brain by macrophages and dendritic cells as a result of better camouflage. On day 35 post-infection these levels became higher in the brains of mice infected with the PRU Δ KU80 strains. This presumably reflects a faster secretion of IL-12 upon infection with the knock-out *P18* versus a delayed one that shows up only 5 weeks post-infection upon infection with the wild type PRU Δ KU80 parasites, a result that can be due to the number of parasites of each strains reaching the brain at a different time point (4 weeks for PRU Δ KU80 Δ P18 and 5 weeks for PRU Δ KU80).




Figure 18. IL-12 transcription levels on days 14, 21, 28, 35 post-infection Brains of mice infected with Pru Δ KU80 (black) and those of mice infected with PRU Δ KU80 Δ P18 (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

E. PRU Δ KU80 Δ P18 induce significantly higher levels of transcription of IFN- γ when compared to PRU Δ KU80

IFN- γ is possibly the most studied of all secreted or transcribed cytokines in case of *T. gondii* infections, due to its significant various roles in controlling the acute infection, stimulating the switch to the chronic infection through its effect on inducing NO secretion and maintaining the infection in its chronic state (Yarovinsky, 2014).

We have measured the transcription levels of IFN- γ in the brains of mice infected with either strains of parasites and showed that IFN- γ transcription is higher in the brains of mice infected with the *P18* knock-out strain on days 14 and 21 post-infection, and peaking on day 21 post-infection. This is likely due to higher parasite burden in case of *P18* knock-out-strain infections (Figure 19). It is also an indication of the possibility of higher NO secretion by microglia and macrophages and by extension of a higher cyst burden in the brains of mice infected with the knock-out strain, firstly due to a higher parasite burden and secondly due to a more effective trigger towards the cyst stage transformation.




Figure 19. Transcription levels of IFN- γ on days 14, 21, 28, 35 post-infection Brains of mice infected with Pru Δ KU80 (black) and those of mice infected with Pru Δ KU80 Δ P18 (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

F. PRU Δ KU80 Δ P18 and PRU Δ KU80 display a gradual increase of TNF- α in the brain of C57BL/6 mice over weeks post-infection with significantly higher levels of transcription of TNF- α in case of the P18 depleted strain

TNF- α works synergistically with IFN- γ to promote the secretion of NO by macrophages and microglia (Deckert-Schlüter, 1998). We have shown that IFN- γ levels are higher in the brains of mice infected with the P18 knock-out strain on days 14 and 21 post-infection (Figure 19). When we assessed TNF- α transcription levels, we noticed a gradual increase in mice infected with either one of the two strains over weeks post-infection. Yet, TNF- α transcription levels were higher in the knock-out-infected mice brains on days 14 and 21 post-infection, while on days 28 and 35 post-infection ($P \leq 0.01$), the conditions shifted to higher levels of TNF- α transcription in mice infected with the wild type strain.

This may be indicative of a larger parasitic load interacting with the parasites, which later decreases in the *P18* knock-out infected mice brains upon better induction of more effective brain cyst formation as compared to the wild type strain.




Figure 20. Transcription levels of TNF- α on days 14, 21, 28, 35 post-infection Brains of mice infected with Pru Δ KU80 (black) and those of mice infected with Pru Δ KU80 Δ P18 (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

G. PRU Δ KU80 Δ P18 and PRU Δ KU80 display a different pattern of IL-6 transcript stimulation in the brain of C57BL/6 mice over weeks post-infection with peaks of IL-6 reached at d21 post-infection with PRU Δ KU80 Δ P18

The pro-inflammatory IL-6 secreted by T lymphocytes is ultimately a product of toxoplasmic antigen priming of T lymphocytes by APCs (Nagineni, Detrick, and Hooks, 2000). We have shown that IL-6 transcription levels progressively increase

from day 14 till day 35 post-infection with the PRU Δ KU80 strain. However, in the P18 knock-out counterpart, the level of transcription of IL-6 reaches its peak on day 21 post-infection ($P \leq 0.01$) to diminish on the subsequent weeks.




Figure 21 Transcription levels of IL-6 on days 14, 21, 28, 35 post-infection Brains of mice infected with Pru Δ KU80 (black) and those of mice infected with PRU Δ KU80 Δ P18 (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

This may suggest that P18 raises the level of IL-6 secretion because of a higher number of parasites reaching the brain upon deleting the gene. This might explain the higher levels of IL-6 secreted in the brain of mice infected with the Pru Δ KU80 Δ P18 on day 21 while this is not the case on day 35 post-infection (Figure 21) when these parasites could have switched to a bradyzoite cyst-hiding stance.

H. *PRUΔKU80ΔP18* and *PRUΔKU80* display a different pattern of IL-1 β transcript levels regulation in the brain of C57BL/6 mice over weeks post-infection

IL-1 β is another pro-inflammatory cytokine secreted mainly by CD4⁺ T lymphocytes (Naginei, Detrick, and Hooks, 2000). Initial measurements of IL-1 β on day 14 post-infection were higher in the brains of mice infected with the knock-out strain. These results shift following day 21 post-infection to become higher in the brains of mice infected with the *PRUΔKU80* strain as shown on day 28 post-infection ($P \leq 0.01$).

These results are consistent with those of IL-6 and other cytokines, shown to be initially higher in the brain of mice harboring the *P18* knock-out strain on days 14 and 21 post-infection and later dropping on days 28 and 35 post-infection below the transcription levels found in the brains of mice with the *PRUΔKU80* strain infection (Figure 22).




Figure 22. Transcription levels of IL-1 β on days 14, 21, 28, 35 post-infection Brains of mice infected with Pru Δ KU80 (black) and those of mice infected with Pru Δ KU80 Δ P18 (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

I. **Pru Δ KU80 Δ P18 induces consistently higher levels of iNOS than Pru Δ KU80 in the brain of C57BL/6 mice over weeks post-infection**

iNOS is the enzyme behind the secretion of NO from L-arginine found in the cytoplasm of macrophages and microglia (Aktan, 2004). NO is essential in the shift from the tachyzoite to the bradyzoite stage (Melo et al., 2011), the control of the acute infection and the establishment of the chronic one.

Our results show that the transcription levels of iNOS (inducible NO synthase) enzyme, reflecting NO secretions are over-all higher in the brains of mice infected with the P18 knock-out strain. They keep rising till day 35 post-infection.




Figure 23. Transcription levels of iNOS on days 14, 21, 28, 35 post-infection Brains of mice infected with *PruΔKU80* (black) and those of mice infected with *PRUΔKU80ΔP18* (dotted) (n=4 mice) each. P value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's T-test.

Bearing in mind that tachyzoite to bradyzoite conversion is present at the initial site of infection, before reaching the brain (Dubey, 1998), due to local effects of the immune system and specifically that of NO, parasites converting to the bradyzoite stage from the *PRUΔKU80ΔP18* strain may be less effectively cleared out and therefore are reaching the brain in larger quantities. Assuming this is true then the surface marker P18 would be playing an antigenic role that permits better parasite detection and clearance by the host's immune system.

The higher levels of NO, as reflected by higher transcription levels of iNOS in the brains of mice infected with the *P18* knock-out strain (Figure 23) could also be

resulting from possible stimulation of a larger number of immune cells, by a bigger parasite load. This may be more effective in inducing the transformation into the bradyzoite stage inside cysts and poses a good justification for the results of previous histopathological examinations (obtained in our lab and not shown) showing a larger number of cysts found in the brains of mice infected with the knock-out strain.

J. *PRUΔKU80ΔP18* induces higher levels of IL-10 than *PRUΔKU80* in the brain of C57BL/6 mice

IL-10 is an anti-inflammatory cytokine that functions in dampening down the immune response and is essential for both host and parasite survival (Aliberti et al., 2005), its secretion comes highest as reflected by its transcriptions levels in accordance with highest NO levels as well as with the progression of the disease further into the chronic phase. Intracellular type II parasites residing within PVs have demonstrated a capacity to promote IL-10 secretion by hijacking the STAT3 pathway on which the host cells rely for the secretion of IL-10 (Melo, Jensen and Saeij, 2011).

We have seen that IL-10 transcription is higher in the brains of mice harboring the knock-out strain on day 35 post-infection This coincides with the highest transcription levels of iNOS. So higher levels of IL-10 in the brains of mice infected with the knock-out strain can also be due to a higher load of parasites promoting IL-10 secretion.

On days 14 and 21 post-infection, mice brains infected with either strain of the parasite showed no detectable levels of IL-10 mRNA transcripts. This may be

explained by a stimulated but delayed secretion of the anti-inflammatory IL-10 cytokine to alleviate the parasite burden in the brain.



Figure 24. Transcription levels of IL-10 on days 14, 21, 28, 35 post-infection Brains of mice infected with *PruΔKU80* (black) and those of mice infected with *PRUΔKU80ΔP18* (dotted) ($n=4$ mice) each. *P* value: between 0.01-0.05 corresponds to *, between 0.01-0.001 corresponds to ** and less than 0.001 corresponds to *** using student's *T*-test.

CONCLUSION

Toxoplasma gondii is one of the most important parasites affecting almost one third of the world's population (Dubey, 2009). Its ability to switch between the tachyzoite and bradyzoite stages has made it a highly successful parasite in eluding the immune response and thereby establishing a chronic infection within its hosts and increasing its chances of propagation in nature. The switch between these two stages is yet to be fully understood.

Among the distinctive features between tachyzoites and bradyzoites are specific stage markers, each serving a role in the respective stage during which they are secreted. Understanding the roles and specific functions of these markers brings us closer to understanding these stages themselves and the switch that takes place between them, its driving factors, causes, mechanisms, and results.

P18, the bradyzoite surface marker coded for by the *P18* gene which was sequenced and published in 1996 (Ödberg-Ferragut et al., 1996) had yet unknown function, and our lab is trying to unravel its function through its deletion using the PRU Δ KU80 type II strain. Our lab showed a higher capacity of forming brain cysts in the *P18* knock-out strain using the Swiss Webster mouse model. Furthermore, a failure of reactivation was observed upon immunosuppression with dexamethasone (Tawil, Diss. 2014).

Due the difference of the immune backgrounds in different mouse models, we first questioned whether the cyst phenotype was also obtained in the C57BL/6 mouse model. Our results on the transcription levels of BAG-1 have allowed us to

verify not only the presence of the parasite in the brains of our mice, but also the presence of a higher bradyzoite load in the brains of mice infected with the *P18* knock-out strain as compared to the brains of mice infected with the PRU Δ KU80 strain (Figure 16).

Since the host immune system is the key factor that controls the back and forth switch between tachyzoites and bradyzoites, this prompted us to conduct the first immune studies in relation to the bradyzoite surface marker P18, by measuring and comparing the transcription levels of several important cytokines involved in the immune response. Since the immune response against *T.gondii* is centered mostly around macrophages and dendritic cells as well as microglia in the brain (Yarovinsky et al., 2014), we opted to center our studies around the cytokines that affect them and are secreted by them, alongside with MCP-1, an important chemoattractant of these cells.

Our results showed increased transcription levels of MCP-1 in the brains of mice infected with the *P18* knock-out strains, this was significantly obvious on days 14 and 21 post-infection ($P \leq 0.01$) (Figure 17) this was followed by significantly higher levels of IL-12 in these mice on day 28 p.i ($P \leq 0.05$) (Figure 18). MCP-1 is a recruiter of macrophages and dendritic cells and IL-12 is a product of their interaction with the parasites.

Under the effect of higher IFN- γ in the brains of mice harboring the P18 knock-out strain, visible mainly on day 21 post-infection (Figure 19), more NO seems to be produced by macrophages and microglia in the brain as reflected by higher iNOS transcription levels in these mice especially on days 28 ($P \leq 0.01$) and 35 ($P \leq 0.05$) post-infection (Figure 23). The remaining cytokine transcription levels fall into place to

support our conclusions. We can see that in the case of pro-inflammatory cytokines mainly released by CD4⁺ T lymphocytes (Nagineni, Detrick, and Hooks, 2000) are usually significantly higher ($P \leq 0.01$) on days 21 post-infection in the brains of mice harboring the *P18* knock-out strain (Figures 21 and 22), a result that changes on day 28 post-infection to become significantly higher in those infected with the PRU Δ KU80 strain ($P \leq 0.01$). On the other hand, we see that the transcription levels of the anti-inflammatory IL-10 is significantly higher ($P \leq 0.05$) in the brains of mice infected with the *P18* knock-out strain on day 35 post-infection (Figure 24)

In conclusion, we postulate that the surface marker P18 expressed on the surface of *T. gondii* bradyzoites by the *P18* gene plays an antigenic role that aids in further stimulation of the immune response. In that sense, the *P18* knock-out strain becomes superior at camouflaging itself from the immune response. The *P18* knock-out strains also seems to cause less stimulation of pro-inflammatory cytokines on the long run, either due to initially higher levels of NO forcing it more efficiently into earlier and more effective latency or due to the knock-out strain's ability to more readily convert from the tachyzoite into the bradyzoite stage and chronic latency.

Our results from the transcription levels of cytokines seem to support the theory that more parasites are reaching the brain and therefore are being prone to less destruction on their way from the primary site of infection. In addition we observe higher levels of IFN- γ and iNOS transcription in the brains of mice infected with the knock-out PRU Δ KU80 Δ P18 strain. The amount of IFN- γ and iNOS (Figures 19 and 23) positively correlates with the higher number of cysts that appear to be in the brains of mice infected with the knock-out strain (Figure 16).

This is not the first step in investigating P18, albeit it is the first on the immunological level. The findings have been encouraging in opening the door to examine and study more surface markers belonging to the P18 family and investigating their roles. Future investigations of P18 should focus on identifying receptors for these bradyzoite surface antigens on the cells of the immune system as well as examining the role of P18 during the acute phase of the infection, if present.

REFERENCES

Afonso, E., P. Thulliez, and E. Gilot-Fromont. "Local meteorological conditions, dynamics of seroconversion to *Toxoplasma gondii* in cats (*Felis catus*) and oocyst burden in a rural environment." *Epidemiology and Infection* 138.08 (2010): 1105-1113.

Aktan, Fugen. "iNOS- mediated NO production and its regulation." *Life sciences* 75.6 (2004): 639-653.

Alexander, David L., et al. "Identification of the moving junction complex of *Toxoplasma gondii*: a collaboration between distinct secretory organelles." *PLoS Pathog* 1.2 (2005): e17.

Aliberti, Julio. "Host persistence: exploitation of anti-inflammatory pathways by *Toxoplasma gondii*." *Nature Reviews Immunology* 5.2 (2005): 162-170.

Bannister, L. H. & Mitchell, G. H. 1989. The fine-structure of secretion by *Plasmodium knowlesi* merozoites during red-cell invasion *Journal of Protozoology*, 36, 362-367.

Bennouna, Soumaya, et al. "Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection." *The Journal of Immunology* 171.11 (2003): 6052-6058.

Black, Michael W., and John C. Boothroyd. "Lytic cycle of *Toxoplasma gondii*." *Microbiology and Molecular Biology Reviews* 64.3 (2000): 607-623.

Blanchard, N., I. R. Dunay, and D. Schlüter. "Persistence of *Toxoplasma gondii* in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system." *Parasite immunology* 37.3 (2015): 150-158.

Bliss, Susan K., et al. "Human polymorphonuclear leukocytes produce IL-12, TNF- α , and the chemokines macrophage-inflammatory protein-1 α and-1 β in response to *Toxoplasma gondii* antigens." *The Journal of Immunology* 162.12 (1999): 7369-7375.

Bliss, Susan K., et al. "Neutrophil depletion during *Toxoplasma gondii* infection leads to impaired immunity and lethal systemic pathology." *Infection and immunity* 69.8 (2001): 4898-4905.

Bliss, Susan K., Yin Zhang, and Eric Y. Denkers. "Murine neutrophil stimulation by *Toxoplasma gondii* antigen drives high level production of IFN- γ -independent IL-12." *The Journal of Immunology* 163.4 (1999): 2081-2088.

Bohne, Wolfgang, et al. "Cloning and characterization of a bradyzoite-specifically expressed gene (hsp30/bag1) of *Toxoplasma gondii*, related to genes encoding small heat-shock proteins of plants." *Molecular microbiology* 16.6 (1995): 1221-1230.

Bollani, Lina, Luisa Strocchio, and Mauro Stronati. "Congenital toxoplasmosis." *Early Human Development* 89 (2013): S70-S72.

Bouhamdan, S. F., et al. "Seroprevalence of *Toxoplasma* antibodies among individuals tested at hospitals and private laboratories in Beirut." *Le Journal medical libanais. The Lebanese medical journal* 58.1 (2009): 8-11.

Butcher, Barbara A., et al. "Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control." *PLoS Pathog* 7.9 (2011): e1002236.

Carruthers, Vern B., and L. David Sibley. "Mobilization of intracellular calcium stimulates microneme discharge in *Toxoplasma gondii*." *Molecular microbiology* 31.2 (1999): 421-428.

Carruthers, Vern, and John C. Boothroyd. "Pulling together: an integrated model of *Toxoplasma* cell invasion." *Current opinion in microbiology* 10.1 (2007): 83-89.

Chao, Chun C., et al. "Human microglial cell defense against *Toxoplasma gondii*. The role of cytokines." *The Journal of Immunology* 152.3 (1994): 1246-1252.

Chen, Jia, et al. "Genetic diversity among *Toxoplasma gondii* strains from different hosts and geographical regions revealed by sequence analysis of GRA5 gene." *Parasites & vectors* 5.1 (2012): 1-6.

Cong, Hua, et al. "Analysis of structures and epitopes of surface antigen glycoproteins expressed in bradyzoites of *Toxoplasma gondii*." *BioMed research international* 2013 (2013).

Cook, A. J. C., et al. "Sources of toxoplasma infection in pregnant women: European multicentre case-control studyCommentary: Congenital toxoplasmosis—further thought for food." *Bmj* 321.7254 (2000): 142-147.

Crawford, Joanna, et al. "Structural characterization of the bradyzoite surface antigen (BSR4) from *Toxoplasma gondii*, a unique addition to the surface antigen glycoprotein 1-related superfamily." *Journal of Biological Chemistry* 284.14 (2009): 9192-9198.

Cross, Joy Barnes. "A cytologic study of *Toxoplasma* with special reference to its effect on the host's cell." *Journal of Infectious Diseases* 80.3 (1947): 278-296.

Dabritz, Haydee A., et al. "Detection of *Toxoplasma gondii*-like oocysts in cat feces and estimates of the environmental oocyst burden." *Journal of the American Veterinary Medical Association* 231.11 (2007): 1676-1684.

Deckert-Schlüter, Martina, et al. "Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis." *The Journal of Immunology* 160.7 (1998): 3427-3436.

Del Rio, Laura, et al. "*Toxoplasma gondii* triggers myeloid differentiation factor 88-dependent IL-12 and chemokine ligand 2 (monocyte chemoattractant protein 1) responses using distinct parasite molecules and host receptors." *The Journal of Immunology* 172.11 (2004): 6954-6960.

Denkers, Eric Y., and Ricardo T. Gazzinelli. "Regulation and function of T-cell-mediated immunity during *Toxoplasma gondii* infection." *Clinical microbiology reviews* 11.4 (1998): 569-588.

Denkers, Eric Y., et al. "Neutrophils, dendritic cells and *Toxoplasma*." *International journal for parasitology* 34.3 (2004): 411-421.

Desmonts, Georges, and Jacques Couvreur. "Congenital toxoplasmosis: a prospective study of 378 pregnancies." *New England Journal of Medicine* 290.20 (1974): 1110-1116.

Dickerson, Faith, et al. "Antibodies to *Toxoplasma gondii* in individuals with mania." *Bipolar disorders* 16.2 (2014): 129-136.

Dubey, J. P. "Advances in the life cycle of *Toxoplasma gondii*." *International journal for parasitology* 28.7 (1998): 1019-1024.

Dubey, J. P. "History of the discovery of the life cycle of *Toxoplasma gondii*." *International journal for parasitology* 39.8 (2009): 877-882.

Dubey, J. P. "Long-term persistence of *Toxoplasma gondii* in tissues of pigs inoculated with *T. gondii* oocysts and effect of freezing on viability of tissue cysts in pork." *American journal of veterinary research* 49.6 (1988): 910-913.

Dubey, J. P. "Survival of *Toxoplasma gondii* tissue cysts in 0.85-6% NaCl solutions at 4-20 C." *The Journal of parasitology* 83.5 (1997): 946-949.

Dubey, J. P. "The scientific basis for prevention of *Toxoplasma gondii* infection: studies on tissue cyst survival, risk factors and hygiene measures." *Congenital toxoplasmosis*. Springer Paris, 2000. 271-275.

Dubey, J. P., and J. K. Frenkel. "Experimental *Toxoplasma* infection in mice with strains producing oocysts." *The Journal of parasitology* (1973): 505-512.

Dubey, J. P., D. S. Lindsay, and C. A. Speer. "Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts." *Clinical microbiology reviews* 11.2 (1998): 267-299.

Dubey, J. P., et al. "Oocyst-induced murine toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed *Toxoplasma gondii* oocysts." *The Journal of parasitology* 83.5 (1997): 870-882.

Dubey, J. P., et al. "Sporulation and survival of *Toxoplasma gondii* oocysts in different types of commercial cat litter." *Journal of Parasitology* 97.5 (2011): 751-754.

Dubey, Jitender P. "The history and life cycle of *Toxoplasma gondii*." *Toxoplasma Gondii (Second Edition)* (2014): 1-17.

Dubey, Jitender P. *Toxoplasmosis of animals and humans*. CRC press, 2009.

Dubremetz, Jean François. "Rhoptries are major players in *Toxoplasma gondii* invasion and host cell interaction." *Cellular microbiology* 9.4 (2007): 841-848.

Dumètre, Aurélien, and Marie-Laure Dardé. "How to detect *Toxoplasma gondii* oocysts in environmental samples?." *FEMS microbiology reviews* 27.5 (2003): 651-661.

Dzierszinski, Florence, et al. "Differential expression of two plant-like enolases with distinct enzymatic and antigenic properties during stage conversion of the

protozoan parasite *Toxoplasma gondii*." *Journal of molecular biology* 309.5 (2001): 1017-1027.

El Hajj, Hiba, et al. "Inverted topology of the *Toxoplasma gondii* ROP5 rhoptry protein provides new insights into the association of the ROP2 protein family with the parasitophorous vacuole membrane." *Cellular microbiology* 9.1 (2007): 54-64.

El Hajj, Hiba, et al. "The ROP2 family of *Toxoplasma gondii* rhoptry proteins: proteomic and genomic characterization and molecular modeling." *Proteomics* 6.21 (2006): 5773-5784.

Federhen, Scott. "The NCBI taxonomy database." *Nucleic acids research* 40.D1 (2012): D136-D143.

Ferguson, D. J. P., and W. M. Hutchison. "An ultrastructural study of the early development and tissue cyst formation of *Toxoplasma gondii* in the brains of mice." *Parasitology research* 73.6 (1987): 483-491.

Ferguson, David JP. "Toxoplasma gondii: 1908-2008, homage to Nicolle, Manceaux and Splendore." *Memórias do Instituto Oswaldo Cruz* 104.2 (2009): 133-148.

Fox, Barbara A., et al. "Efficient gene replacements in *Toxoplasma gondii* strains deficient for nonhomologous end joining." *Eukaryotic cell* 8.4 (2009): 520-529.

Fox, Barbara A., et al. "Type II *Toxoplasma gondii* KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection." *Eukaryotic cell* 10.9 (2011): 1193-1206.

Frenkel, J. K. "Pathogenesis of toxoplasmosis and of infections with organisms resembling *Toxoplasma*." *Annals of the New York Academy of Sciences* 64.2 (1956): 215-251.

Frenkel, J. K., et al. "Prospective vaccine prepared from a new mutant of *Toxoplasma gondii* for use in cats." *American journal of veterinary research* 52.5 (1991): 759-763.

Gazzinelli, Ricardo T., et al. "In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4⁺ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha." *The Journal of Immunology* 157.2 (1996): 798-805.

Gazzinelli, Ricardo T., et al. "Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with *Toxoplasma gondii*." *The Journal of Immunology* 153.6 (1994): 2533-2543.

Gómez-Marin, Jorge Enrique, et al. "First Colombian multicentric newborn screening for congenital toxoplasmosis." *PLoS Negl Trop Dis* 5.5 (2011): e1195.

Gustafson, Paul V., Hilda D. Agar, and Dorothy I. Cramer. "An electron microscope study of *Toxoplasma*." *The American journal of tropical medicine and hygiene* 3.6 (1954): 1008-1021.

Hamdani, Nora, et al. "Relationship between *Toxoplasma gondii* infection and bipolar disorder in a French sample." *Journal of affective disorders* 148.2 (2013): 444-448.

Herwaldt, Barbara L. "Laboratory-acquired parasitic infections from accidental exposures." *Clinical microbiology reviews* 14.4 (2001): 659-688.

Hunter, C. A., & Sibley, L. D. (2012). Modulation of innate immunity by toxoplasma gondii virulence effectors.

Hunter, C. A., R. Chizzonite, and J. S. Remington. "IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens." *The Journal of Immunology* 155.9 (1995): 4347-4354.

Hunter, Christopher A., et al. "Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha." *Infection and immunity* 62.7 (1994): 2818-2824.

Hutchison, W. M., et al. "The life cycle of the coccidian parasite, Toxoplasma gondii, in the domestic cat." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 65.3 (1971): 380-398.

Isaac-Renton, Judith, et al. "Detection of Toxoplasma gondii oocysts in drinking water." *Applied and environmental microbiology* 64.6 (1998): 2278-2280.

Jacobs, Leon, Jack S. Remington, and Marjorie L. Melton. "The resistance of the encysted form of Toxoplasma gondii." *The Journal of parasitology* (1960): 11-21.

Jebbari, H., et al. "A protective role for IL-6 during early infection with Toxoplasma gondii." *Parasite immunology* 20.5 (1998): 231-240.

Jones-Brando, Lorraine, E. Fuller Torrey, and Robert Yolken. "Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of *Toxoplasma gondii*." *Schizophrenia research* 62.3 (2003): 237-244.

Kafsack, Björn FC, Vern B. Carruthers, and Fernando J. Pineda. "Kinetic modeling of *Toxoplasma gondii* invasion." *Journal of theoretical biology* 249.4 (2007): 817-825.

KHAN, IMTIAZ A., TADASHI MATSUURA, and LLOYD H. KASPER. "IL-10 mediates immunosuppression following primary infection with *Toxoplasma gondii* in mice." *Parasite immunology* 17.4 (1995): 185-195.

Kim, Kami, and Louis M. Weiss. "Toxoplasma gondii: the model apicomplexan." *International journal for parasitology* 34.3 (2004): 423-432.

Koppe, J. G., D. H. Loewer-Sieger, and H. de Roever-Bonnet. "Results of 20-year follow-up of congenital toxoplasmosis." *The Lancet* 327.8475 (1986): 254-256.

Kotula, A. W., et al. "Effect of freezing on infectivity of *Toxoplasma gondii* tissue cysts in pork." *Journal of Food Protection*® 54.9 (1991): 687-690.

Kumar, Himanshu, Taro Kawai, and Shizuo Akira. "Toll-like receptors and innate immunity." *Biochemical and biophysical research communications* 388.4 (2009): 621-625.

Kuticic, V., and Teodor Wikerhauser. "Studies of the effect of various treatments on the viability of *Toxoplasma gondii* tissue cysts and oocysts." *Toxoplasma gondii*. Springer Berlin Heidelberg, 1996. 261-265.

Laliberte, Julie, and Vernon B. Carruthers. "Host cell manipulation by the human pathogen *Toxoplasma gondii*." *Cellular and molecular life sciences* 65.12 (2008): 1900-1915.

Lambert, Henrik, et al. "Induction of dendritic cell migration upon *Toxoplasma gondii* infection potentiates parasite dissemination." *Cellular microbiology* 8.10 (2006): 1611-1623.

Lebrun, Maryse, et al. "The rhoptry neck protein RON4 relocalizes at the moving junction during *Toxoplasma gondii* invasion." *Cellular microbiology* 7.12 (2005): 1823-1833.

Lee, J. J., Leedale, G. F. & Bradbury, P. (eds.) 2000. An illustrated guide to the Protozoa, Kansas: Society of Protozoologists.

Lekutis, Christine, David JP Ferguson, and John C. Boothroyd. "Toxoplasma gondii: identification of a developmentally regulated family of genes related to SAG2." *Experimental parasitology* 96.2 (2000): 89-96.

Levine, Norman D. "Taxonomy of *Toxoplasma*." *The Journal of protozoology* 24.1 (1977): 36-41.

Louveau, Antoine, et al. "Structural and functional features of central nervous system lymphatic vessels." *Nature* (2015).

Lyons, Russell E., Rima McLeod, and Craig W. Roberts. "Toxoplasma gondii tachyzoite–bradyzoite interconversion." *Trends in parasitology* 18.5 (2002): 198-201.

Manger, Ian D., Adrian B. Hehl, and John C. Boothroyd. "The surface of *Toxoplasma* tachyzoites is dominated by a family of glycosylphosphatidylinositol-anchored antigens related to SAG1." *Infection and immunity* 66.5 (1998): 2237-2244.

Manguin, S., Bangs, M. J., Pothikasikorn, J. & Chareonviriyaphap, T. 2010. Review on global co-transmission of human *Plasmodium* species and *Wuchereria bancrofti* by *Anopheles* mosquitoes. *Infection Genetics and Evolution*, 10, 159-177.

McAuley, James B. "Congenital toxoplasmosis." *Journal of the Pediatric Infectious Diseases Society* 3.suppl 1 (2014): S30-S35.

Melo, Mariane B., Kirk DC Jensen, and Jeroen PJ Saeij. "Toxoplasma gondii effectors are master regulators of the inflammatory response." *Trends in parasitology* 27.11 (2011): 487-495.

Miller, Catherine M., et al. "The immunobiology of the innate response to *Toxoplasma gondii*." *International journal for parasitology* 39.1 (2009): 23-39.

Montoya, Jose G. "Laboratory diagnosis of *Toxoplasma gondii* infection and toxoplasmosis." *Journal of Infectious Diseases* 185.Supplement 1 (2002): S73-S82.

Montoya, Jose G., et al. "Human CD4+ and CD8+ T lymphocytes are both cytotoxic to *Toxoplasma gondii*-infected cells." *Infection and immunity* 64.1 (1996): 176-181.

Munoz, Melba, Oliver Liesenfeld, and Markus M. Heimesaat. "Immunology of *Toxoplasma gondii*." *Immunological reviews* 240.1 (2011): 269-285.

Nagineeni, Chandrasekharam N., Barbara Detrick, and John J. Hooks.

"Toxoplasma gondii infection induces gene expression and secretion of interleukin 1 (IL-1), IL-6, granulocyte-macrophage colony-stimulating factor, and intercellular adhesion molecule 1 by human retinal pigment epithelial cells." *Infection and immunity* 68.1 (2000): 407-410.

Neyer, Lauri Ellis, et al. "Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii." *Infection and immunity* 65.5 (1997): 1675-1682.

Nicolle, Charles, and L. Manceaux. "Sur une infection à corps de Leishman (ou organismes voisins) du gondii." *CR Acad Sci* 147.763 (1908).

Ödberg-Ferragut, Carmen, et al. "Molecular cloning of the Toxoplasma gondii sag4 gene encoding an 18 kDa bradyzoite specific surface protein." *Molecular and biochemical parasitology* 82.2 (1996): 237-244.

Ong, Yi-Ching, Michael L. Reese, and John C. Boothroyd. "Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6." *Journal of Biological Chemistry* 285.37 (2010): 28731-28740.

Opitz, Corinna, and Dominique Soldati. "'The glideosome': a dynamic complex powering gliding motion and host cell invasion by Toxoplasma gondii." *Molecular microbiology* 45.3 (2002): 597-604.

Parlog, A., D. Schlüter, and I. R. Dunay. "Toxoplasma gondii-induced neuronal alterations." *Parasite immunology* 37.3 (2015): 159-170.

Pelloux, H., et al. "Influence of cytokines on *Toxoplasma gondii* growth in human astrocytoma-derived cells." *Parasitology research* 82.7 (1996): 598-603.

Robert-Gangneux, Florence, and Marie-Laure Dardé. "Epidemiology of and diagnostic strategies for toxoplasmosis." *Clinical microbiology reviews* 25.2 (2012): 264-296.

Rose, A. G., et al. "Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantation." *Archives of pathology & laboratory medicine* 107.7 (1983): 368-373.

Salviz, Mehti, et al. "Otopathology in congenital toxoplasmosis." *Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology* 34.6 (2013): 1165.

Scanga, Charles A., et al. "Cutting edge: MyD88 is required for resistance to *Toxoplasma gondii* infection and regulates parasite-induced IL-12 production by dendritic cells." *The Journal of Immunology* 168.12 (2002): 5997-6001.

Schmidt, Dorte Remmer, et al. "The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999–2002." *Archives of disease in childhood* 91.8 (2006): 661-665.

Schmittgen, Thomas D., and Kenneth J. Livak. "Analyzing real-time PCR data by the comparative CT method." *Nature protocols* 3.6 (2008): 1101-1108.

Speer, C. A., and J. P. Dubey. "Ultrastructure of early stages of infections in mice fed *Toxoplasma gondii* oocysts." *Parasitology* 116.01 (1998): 35-42.

Splendore, A. "Un nuovo protozoa parassita deconigli incontrato nelle lesioni anatomiche d'une malattia che ricorda in molti punti il Kala-azar dell'uoma. Nota preliminare pel." *Rev Soc Sci Sao Paulo* 3 (1908): 109-112.

Stegmann, Barbara J., and J. Christopher Carey. "TORCH Infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections." *Current women's health reports* 2.4 (2002): 253-258.

Suzuki, Y., et al. "Cerebral toxoplasmosis: pathogenesis and host resistance." WEISS, L.; KIM, K. *Toxoplasma gondii: the model apicomplexan. Perspectives and methods. Rio de Janeiro: Elsevier* (2007): 567-591.

Taccioli, Guillermo E., et al. "Ku80: product of the XRCC5 gene and its role in DNA repair and V (D) J recombination." *Science* 265.5177 (1994): 1442-1445.

Tait, Elia D., and Christopher A. Hunter. "Advances in understanding immunity to *Toxoplasma gondii*." *Memorias do Instituto Oswaldo Cruz* 104.2 (2009): 201-210.

Takeda, Kiyoshi, Tsuneyasu Kaisho, and Shizuo Akira. "Toll-like receptors." *Annual review of immunology* 21.1 (2003): 335-376.

Tawil, Nadim M. *Knock-out of the bradyzoite marker P18 in Toxoplasma gondii: insights towards a functional characterization during neurotoxoplasmosis*. Diss. 2014.

Tenter, Astrid M., Anja R. Heckerroth, and Louis M. Weiss. "Toxoplasma gondii: from animals to humans." *International journal for parasitology* 30.12 (2000): 1217-1258.

Tomavo, S. T. A. N. I. S. L. A. S., et al. "Characterization of bradyzoite-specific antigens of Toxoplasma gondii." *Infection and Immunity* 59.10 (1991): 3750-3753.

Torrey, E. Fuller, and Robert H. Yolken. "Toxoplasma gondii and schizophrenia." *Emerging infectious diseases* 9.11 (2003): 1375-1380.

Ueno, Norikiyo, and Melissa B. Lodoen. "From the blood to the brain: avenues of eukaryotic pathogen dissemination to the central nervous system." *Current opinion in microbiology* 26 (2015): 53-59.

Wang, Yanhua, and Hong Yin. "Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii." *Parasit Vectors* 7.180 (2014): 24.

Weigel, R. M., et al. "Risk factors for infection with Toxoplasma gondii for residents and workers on swine farms in Illinois." *The American journal of tropical medicine and hygiene* 60.5 (1999): 793-798.

Weiss, Louis M., and Kami Kim. "The development and biology of bradyzoites of *Toxoplasma gondii*." *Frontiers in bioscience: a journal and virtual library* 5 (2000): D391.

Weiss, Louis M., and Kami Kim. *Toxoplasma gondii: the model apicomplexan. Perspectives and methods*. Academic Press, 2011.

Wilson, Emma H., et al. "A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis." *Journal of neuroimmunology* 165.1 (2005): 63-74.

Wolf, Abner, David Cowen, and Beryl Paige. "Human toxoplasmosis: occurrence in infants as an encephalomyelitis verification by transmission to animals." *Science* 89.2306 (1939): 226-227.

Wong, Sin-Yew, and Jack S. Remington. "Toxoplasmosis in pregnancy." *Clinical Infectious Diseases* (1994): 853-861.

Yang, Shumin, and Stephen F. Parmley. "Toxoplasma gondii expresses two distinct lactate dehydrogenase homologous genes during its life cycle in intermediate hosts." *Gene* 184.1 (1997): 1-12.

Yarovinsky, Felix. "Innate immunity to *Toxoplasma gondii* infection." *Nature Reviews Immunology* 14.2 (2014): 109-121.

Yarovinsky, Felix. "Toll-like receptors and their role in host resistance to *Toxoplasma gondii*." *Immunology letters* 119.1 (2008): 17-21.